WO2022139526A1 - 지질 나노입자를 포함하는 암 예방 또는 치료용 조성물 - Google Patents
지질 나노입자를 포함하는 암 예방 또는 치료용 조성물 Download PDFInfo
- Publication number
- WO2022139526A1 WO2022139526A1 PCT/KR2021/019773 KR2021019773W WO2022139526A1 WO 2022139526 A1 WO2022139526 A1 WO 2022139526A1 KR 2021019773 W KR2021019773 W KR 2021019773W WO 2022139526 A1 WO2022139526 A1 WO 2022139526A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- mol
- lipid
- pharmaceutical composition
- lipid nanoparticles
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 257
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 202
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 160
- 201000011510 cancer Diseases 0.000 title claims abstract description 131
- 239000000203 mixture Substances 0.000 title abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 78
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 70
- 238000011282 treatment Methods 0.000 claims abstract description 60
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 47
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 44
- 238000001959 radiotherapy Methods 0.000 claims abstract description 31
- 210000004027 cell Anatomy 0.000 claims description 177
- 229920001223 polyethylene glycol Polymers 0.000 claims description 101
- 108020004459 Small interfering RNA Proteins 0.000 claims description 96
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 72
- 229940079593 drug Drugs 0.000 claims description 71
- 229920002477 rna polymer Polymers 0.000 claims description 39
- 235000012000 cholesterol Nutrition 0.000 claims description 36
- 102000039446 nucleic acids Human genes 0.000 claims description 35
- 108020004707 nucleic acids Proteins 0.000 claims description 35
- 150000007523 nucleic acids Chemical class 0.000 claims description 35
- -1 POPE Chemical compound 0.000 claims description 34
- 102000004169 proteins and genes Human genes 0.000 claims description 32
- 150000003904 phospholipids Chemical class 0.000 claims description 30
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 28
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 28
- 201000010881 cervical cancer Diseases 0.000 claims description 28
- 239000002202 Polyethylene glycol Substances 0.000 claims description 24
- 102000053602 DNA Human genes 0.000 claims description 23
- 108020004414 DNA Proteins 0.000 claims description 23
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 23
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 23
- 201000005202 lung cancer Diseases 0.000 claims description 23
- 208000020816 lung neoplasm Diseases 0.000 claims description 23
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 23
- 201000002528 pancreatic cancer Diseases 0.000 claims description 23
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 23
- 125000000129 anionic group Chemical group 0.000 claims description 17
- 229940106189 ceramide Drugs 0.000 claims description 17
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 16
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 16
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 16
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 15
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 14
- 206010006187 Breast cancer Diseases 0.000 claims description 13
- 208000026310 Breast neoplasm Diseases 0.000 claims description 13
- 241000701806 Human papillomavirus Species 0.000 claims description 9
- 108091034117 Oligonucleotide Proteins 0.000 claims description 9
- 229960004316 cisplatin Drugs 0.000 claims description 9
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 9
- 108091023037 Aptamer Proteins 0.000 claims description 8
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 claims description 7
- 239000004055 small Interfering RNA Substances 0.000 claims description 7
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 6
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 6
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 6
- 239000002679 microRNA Substances 0.000 claims description 6
- 108090000994 Catalytic RNA Proteins 0.000 claims description 5
- 102000053642 Catalytic RNA Human genes 0.000 claims description 5
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 5
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 5
- 201000010536 head and neck cancer Diseases 0.000 claims description 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 5
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 108091092562 ribozyme Proteins 0.000 claims description 5
- HKJAWHYHRVVDHK-UHFFFAOYSA-N 15,16,17-trihydroxyhentriacontane-14,18-dione Chemical compound CCCCCCCCCCCCCC(=O)C(O)C(O)C(O)C(=O)CCCCCCCCCCCCC HKJAWHYHRVVDHK-UHFFFAOYSA-N 0.000 claims description 4
- 206010061424 Anal cancer Diseases 0.000 claims description 4
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 4
- 206010034299 Penile cancer Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 206010044002 Tonsil cancer Diseases 0.000 claims description 4
- 208000006842 Tonsillar Neoplasms Diseases 0.000 claims description 4
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 4
- 201000011165 anus cancer Diseases 0.000 claims description 4
- 239000002299 complementary DNA Substances 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 206010046885 vaginal cancer Diseases 0.000 claims description 4
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 4
- 201000005102 vulva cancer Diseases 0.000 claims description 4
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 claims description 3
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims description 3
- MPGABYXKKCLIRW-UHFFFAOYSA-N 2-decyloxirane Chemical group CCCCCCCCCCC1CO1 MPGABYXKKCLIRW-UHFFFAOYSA-N 0.000 claims description 3
- AGUDBAONKXJDNO-UHFFFAOYSA-N 3-[4-(3-aminopropyl)piperazin-1-yl]propan-1-amine Chemical compound NCCCN1CCN(CCCN)CC1.NCCCN1CCN(CCCN)CC1 AGUDBAONKXJDNO-UHFFFAOYSA-N 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 3
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims description 3
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 3
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims description 3
- WTBFLCSPLLEDEM-JIDRGYQWSA-N 1,2-dioleoyl-sn-glycero-3-phospho-L-serine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC WTBFLCSPLLEDEM-JIDRGYQWSA-N 0.000 claims description 2
- 206010000830 Acute leukaemia Diseases 0.000 claims description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 206010006143 Brain stem glioma Diseases 0.000 claims description 2
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 claims description 2
- 201000005746 Pituitary adenoma Diseases 0.000 claims description 2
- 206010061538 Pituitary tumour benign Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 2
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 208000000728 Thymus Neoplasms Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 206010046431 Urethral cancer Diseases 0.000 claims description 2
- 206010046458 Urethral neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 201000005188 adrenal gland cancer Diseases 0.000 claims description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 125000001549 ceramide group Chemical group 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000024207 chronic leukemia Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 230000002124 endocrine Effects 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 229960005277 gemcitabine Drugs 0.000 claims description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 201000004962 larynx cancer Diseases 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 2
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 201000008006 pharynx cancer Diseases 0.000 claims description 2
- 208000021310 pituitary gland adenoma Diseases 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 210000003705 ribosome Anatomy 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000002314 small intestine cancer Diseases 0.000 claims description 2
- 206010062261 spinal cord neoplasm Diseases 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 201000009377 thymus cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 claims 2
- DSNRWDQKZIEDDB-SQYFZQSCSA-N 1,2-dioleoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-SQYFZQSCSA-N 0.000 claims 1
- MWRBNPKJOOWZPW-NYVOMTAGSA-N 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-NYVOMTAGSA-N 0.000 claims 1
- 108091027757 Deoxyribozyme Proteins 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 54
- 230000002265 prevention Effects 0.000 abstract description 16
- 229940124597 therapeutic agent Drugs 0.000 abstract description 5
- 230000014509 gene expression Effects 0.000 description 48
- 230000005855 radiation Effects 0.000 description 48
- 239000000562 conjugate Substances 0.000 description 44
- 238000000034 method Methods 0.000 description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- 238000005538 encapsulation Methods 0.000 description 28
- 210000001519 tissue Anatomy 0.000 description 28
- 102100024279 Phosphomevalonate kinase Human genes 0.000 description 24
- 108091000116 phosphomevalonate kinase Proteins 0.000 description 24
- 238000001727 in vivo Methods 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 19
- 238000001890 transfection Methods 0.000 description 18
- 230000001965 increasing effect Effects 0.000 description 17
- 238000012377 drug delivery Methods 0.000 description 16
- 229920005735 poly(methyl vinyl ketone) Polymers 0.000 description 15
- 230000035945 sensitivity Effects 0.000 description 15
- 150000001412 amines Chemical class 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 13
- 230000007423 decrease Effects 0.000 description 12
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 108091093037 Peptide nucleic acid Proteins 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 229920002113 octoxynol Polymers 0.000 description 10
- 230000002441 reversible effect Effects 0.000 description 10
- 108091033409 CRISPR Proteins 0.000 description 9
- 230000000295 complement effect Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 108060001084 Luciferase Proteins 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 8
- 238000002512 chemotherapy Methods 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 230000002708 enhancing effect Effects 0.000 description 8
- 238000004020 luminiscence type Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 7
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 7
- 101100540311 Human papillomavirus type 16 E6 gene Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000012790 confirmation Methods 0.000 description 7
- 238000001415 gene therapy Methods 0.000 description 7
- 125000005647 linker group Chemical group 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 6
- 239000005089 Luciferase Substances 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000005415 bioluminescence Methods 0.000 description 6
- 230000029918 bioluminescence Effects 0.000 description 6
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108700011259 MicroRNAs Proteins 0.000 description 5
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000010362 genome editing Methods 0.000 description 5
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- SXAMGRAIZSSWIH-UHFFFAOYSA-N 2-[3-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,2,4-oxadiazol-5-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NOC(=N1)CC(=O)N1CC2=C(CC1)NN=N2 SXAMGRAIZSSWIH-UHFFFAOYSA-N 0.000 description 4
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000005880 cancer cell killing Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000008004 cell lysis buffer Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 238000001476 gene delivery Methods 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 150000003141 primary amines Chemical class 0.000 description 4
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012447 xenograft mouse model Methods 0.000 description 4
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 3
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 3
- XUSNPFGLKGCWGN-UHFFFAOYSA-N 3-[4-(3-aminopropyl)piperazin-1-yl]propan-1-amine Chemical compound NCCCN1CCN(CCCN)CC1 XUSNPFGLKGCWGN-UHFFFAOYSA-N 0.000 description 3
- WTFUTSCZYYCBAY-SXBRIOAWSA-N 6-[(E)-C-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-N-hydroxycarbonimidoyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C/C(=N/O)/C1=CC2=C(NC(O2)=O)C=C1 WTFUTSCZYYCBAY-SXBRIOAWSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000896557 Homo sapiens Eukaryotic translation initiation factor 3 subunit B Proteins 0.000 description 3
- 101000988834 Homo sapiens Hypoxanthine-guanine phosphoribosyltransferase Proteins 0.000 description 3
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 101150063832 Pmvk gene Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108091027544 Subgenomic mRNA Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000009881 electrostatic interaction Effects 0.000 description 3
- 230000012202 endocytosis Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000003197 gene knockdown Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002601 intratumoral effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 2
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 102000008128 Apolipoprotein E3 Human genes 0.000 description 2
- 108010060215 Apolipoprotein E3 Proteins 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 108091079001 CRISPR RNA Proteins 0.000 description 2
- 241000284156 Clerodendrum quadriloculare Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 101150013359 E7 gene Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 208000009608 Papillomavirus Infections Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000004611 cancer cell death Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 238000000604 cryogenic transmission electron microscopy Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229940009976 deoxycholate Drugs 0.000 description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 150000002924 oxiranes Chemical class 0.000 description 2
- 238000011375 palliative radiation therapy Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000013298 xenograft nude mouse model Methods 0.000 description 2
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- WTJKGGKOPKCXLL-VYOBOKEXSA-N 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC WTJKGGKOPKCXLL-VYOBOKEXSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical compound NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
- PVFFUHAAOKXVTK-UHFFFAOYSA-N 2-(methylamino)-4-oxopentanoic acid Chemical compound CNC(C(O)=O)CC(C)=O PVFFUHAAOKXVTK-UHFFFAOYSA-N 0.000 description 1
- IGHBYSOWDNOPJW-UHFFFAOYSA-N 3-piperidin-1-ylpropan-1-amine Chemical compound NCCCN1CCCCC1.NCCCN1CCCCC1 IGHBYSOWDNOPJW-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- JDBGXEHEIRGOBU-UHFFFAOYSA-N 5-hydroxymethyluracil Chemical compound OCC1=CNC(=O)NC1=O JDBGXEHEIRGOBU-UHFFFAOYSA-N 0.000 description 1
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
- CKOMXBHMKXXTNW-UHFFFAOYSA-N 6-methyladenine Chemical compound CNC1=NC=NC2=C1N=CN2 CKOMXBHMKXXTNW-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 description 1
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
- 229960005508 8-azaguanine Drugs 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102000047934 Caspase-3/7 Human genes 0.000 description 1
- 108700037887 Caspase-3/7 Proteins 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 101100329224 Coprinopsis cinerea (strain Okayama-7 / 130 / ATCC MYA-4618 / FGSC 9003) cpf1 gene Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 101150071673 E6 gene Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101100156155 Human papillomavirus type 16 E7 gene Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- OTGQIQQTPXJQRG-UHFFFAOYSA-N N-(octadecanoyl)ethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCO OTGQIQQTPXJQRG-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-UHFFFAOYSA-N N-palmitoyldihydro-sphingosine Natural products CCCCCCCCCCCCCCCC(=O)NC(CO)C(O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-UHFFFAOYSA-N 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920000362 Polyethylene-block-poly(ethylene glycol) Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108091008103 RNA aptamers Proteins 0.000 description 1
- 108010065108 RNA-cleaving DNA 10-23 Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 241000221013 Viscum album Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- IMUDHTPIFIBORV-UHFFFAOYSA-N aminoethylpiperazine Chemical compound NCCN1CCNCC1 IMUDHTPIFIBORV-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- 229960001694 anagrelide Drugs 0.000 description 1
- OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 101150010487 are gene Proteins 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 1
- LNHWXBUNXOXMRL-VWLOTQADSA-N belotecan Chemical compound C1=CC=C2C(CCNC(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 LNHWXBUNXOXMRL-VWLOTQADSA-N 0.000 description 1
- 229950011276 belotecan Drugs 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 101150059443 cas12a gene Proteins 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229960002412 cediranib Drugs 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 125000003374 diacylglycerol group Chemical group 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical group CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 description 1
- 229950005277 gossypol Drugs 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- WDVGLADRSBQDDY-UHFFFAOYSA-N holmium(3+);trinitrate Chemical compound [Ho+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O WDVGLADRSBQDDY-UHFFFAOYSA-N 0.000 description 1
- 108091008147 housekeeping proteins Proteins 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- GZCNJTFELNTSAB-UHFFFAOYSA-N n'-(7h-purin-6-yl)hexane-1,6-diamine Chemical compound NCCCCCCNC1=NC=NC2=C1NC=N2 GZCNJTFELNTSAB-UHFFFAOYSA-N 0.000 description 1
- JWNPDZNEKVCWMY-VQHVLOKHSA-N neratinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 JWNPDZNEKVCWMY-VQHVLOKHSA-N 0.000 description 1
- 229950008835 neratinib Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 229950000193 oteracil Drugs 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000962 poly(amidoamine) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 101150012509 sub gene Proteins 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- ZEMGGZBWXRYJHK-UHFFFAOYSA-N thiouracil Chemical compound O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 229960001771 vorozole Drugs 0.000 description 1
- XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- FHQVHHIBKUMWTI-OTMQOFQLSA-N {1-hexadecanoyl-2-[(Z)-octadec-9-enoyl]-sn-glycero-3-phospho}ethanolamine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC FHQVHHIBKUMWTI-OTMQOFQLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
Definitions
- the present application relates to a composition for preventing or treating cancer comprising lipid nanoparticles.
- the drug delivery system designed to efficiently deliver the required amount of drug by reducing side effects and maximizing efficacy and effect, can create economic benefits comparable to drug development while It is a high value-added core technology with great potential for success, and its purpose is to improve the quality of patient treatment by making drug administration more efficient.
- the solubilization technology of poorly soluble drugs belonging to the drug absorption promotion technology which is one of the core technologies of the drug delivery system, is considered the most reasonable method to reduce the development cost of new drug substances and to increase the added value of currently marketed drugs.
- the development of improved new drugs through the development of drug solubilization technology in a situation where new drug development conditions are poor as in Korea is a field that can create enormous added value at a low cost.
- Gene therapy using gene drug delivery systems holds great promise for correcting genetic linkages and treating numerous diseases.
- effective gene delivery is one of the main tasks, and viral delivery has been demonstrated to be effective in gene delivery.
- drawbacks such as immunogenicity, limitations in the size of injected DNA, and difficulties in mass production, limit the use of viruses as gene delivery systems.
- Non-viral gene carriers such as cationic liposomes and polymers are beginning to gain attention as alternative means of viral systems.
- polymeric carriers The improved stability profile and ease of preparation and manipulation of polymeric carriers have prompted research into the design and synthesis of non-toxic and biodegradable polymeric carriers for effective and safe gene delivery.
- Poly (L-lysine), polyethyleneimine (polyethylenimine), starburst (starburst), polyamidoamine dendrimers, and cationic liposomes can spontaneously self-assemble and plasmid DNA (pDNA) through endocytosis It has been widely studied as a non-viral gene carrier because it can be compressed into structures small enough to enter cells.
- Nucleic acids such as antisense RNA and siRNA, are substances that can inhibit the expression of specific proteins in vivo, and are spotlighted as an important tool for the treatment of cancer, genetic diseases, infectious diseases, autoimmune diseases, etc. (Novina and Sharp, Nature, 430, 161-164, 2004).
- nucleic acids such as siRNA are difficult to deliver directly into cells and are easily degraded by enzymes in the blood, so many studies are being conducted to overcome them.
- lipid-DNA conjugates and polymer-DNA conjugates are positively charged lipids or polymers
- lipid-DNA conjugates and polymer-DNA conjugates are positively charged lipids or polymers
- Lipid-DNA conjugates bind nucleic acids and deliver nucleic acids into cells, and are widely used at the cellular level, but in vivo, when injected locally, in many cases, they induce inflammation in the body (Filonand and Phillips, Biochim. Biophys. Acta, 1329). , 345-356, 1997), there is a disadvantage of accumulating in tissues such as the lung, liver, and spleen, which are mainly the primary organs of passage during intravascular injection (Ren et al., Gene Therapy, 7, 764-768, 2000).
- non-viral carrier has a problem of low transfection efficiency. Although many efforts have been made to increase transfection efficiency, this is still far from a system that is considered stable. In addition, non-viral gene carrier carriers exhibit remarkably high cytotoxicity due to poor biocompatibility and non-biodegradability.
- One example is (1) a 6-membered heterocyclic amine and an alkyl-epoxide bonded ionizable lipid (ionizable lipid); phospholipids; cholesterol; And lipid-lipid nanoparticles comprising a PEG (polyethyleneglycol) conjugate, and
- the first anticancer agent is an anionic drug, a nucleic acid, or a combination thereof,
- Another example is to provide a pharmaceutical composition for the treatment of cancer for use in combination with radiation therapy comprising the pharmaceutical composition.
- Another example is to provide a pharmaceutical composition for combined administration of an anticancer agent, further comprising the pharmaceutical composition and a second anticancer agent.
- ionizable lipid 6-membered heterocyclic amine and alkyl-epoxide bonded ionizable lipid (ionizable lipid); phospholipids; cholesterol; And lipid-lipid nanoparticles comprising a PEG (polyethyleneglycol) conjugate, and
- the first anticancer agent provides an anionic drug, a nucleic acid, or a combination thereof, a pharmaceutical composition for preventing or treating cancer.
- the lipid nanoparticles included in the pharmaceutical composition have excellent biocompatibility and can deliver anticancer agents (eg, gene therapy) with high efficiency, so they are useful in lipid nanoparticle-mediated gene therapy and imaging technology, etc. can be used
- the term 'ionizable lipid' or 'lipidoid' refers to an amine-containing lipid that can be easily protonated, for example, a lipid whose charge state changes depending on the surrounding pH.
- the ionizable lipid may be a 6-membered heterocyclic amine and an alkyl-epoxide bonded thereto.
- the ionizable lipid may be a compound having properties similar to lipids produced by the reaction of a 6-membered heterocyclic amine and an alkyl-epoxide, and more specifically, a 6-membered heterocyclic amine with an alkyl-epoxide It may be a compound produced by a ring opening reaction of an epoxide by reacting.
- 1,4-bis (3-aminopropyl) piperazine (1,4-bis (3-aminopropyl) piperazine) and 1,2-epoxydodecane are mixed in a molar ratio of 1: 4 to 700 It may be prepared by reacting for 2 to 4 days at 800 rpm and 85 to 95° C.
- the ionizable lipid may be protonated (positively charged) at a pH below the pKa of the cationic lipid, and may be substantially neutral at a pH above the pKa.
- the lipid nanoparticles may include protonated ionizable lipids and/or ionizable lipids exhibiting neutrality.
- the ionizable lipid is an ionizable compound having lipid-like properties, such that the drug is highly efficiently encapsulated in lipid nanoparticles through electrostatic interaction with a drug (eg, an anionic drug and/or nucleic acid). can play a role.
- a drug eg, an anionic drug and/or nucleic acid
- the 6-membered heterocyclic amine may have a piperazine or piperidine structure.
- the 6-membered heterocyclic amine may be a chain or non-chain amine including a tertiary amine, and according to one example, , , , , , and It may be at least one selected from the group consisting of.
- the 6-membered heterocyclic amine is 1,4-bis (3-aminopropyl) piperazine (1,4-bis (3-aminopropyl) piperazine), N- (3-aminopropyl) piperidine (N-(3-Aminopropyl)piperidine), (1-methyl-4-piperidinyl)methanamine ((1-Methyl-4-piperidinyl)methanamine), 2-(4-methyl-piperazin-1-yl )-Ethylamine (2-(4-Methyl-piperazin-1-yl)-ethylamine), 1-(2-aminoethyl)piperazine, and 1-(3-amino) It may be at least one selected from the group consisting of propyl) piperazine (1- (3-aminopropyl) piperazine).
- the drug encapsulation rate of the lipid nanoparticles (i) the polydispersity index (PDI) of the lipid nanoparticles, and / or (iii) the cancer of the pharmaceutical composition
- PDI polydispersity index
- lipid When comprising an ionizable lipid comprising an amine, it may have one or more of the following characteristics:
- the size of the prepared lipid nanoparticles is uniform (or has a low PDI value);
- a lipid comprising an ionizable lipid comprising 1,4-bis (3-aminopropyl) piperazine (Cas Nos. 7209-38-3)
- nanoparticles may have one or more of the following characteristics than when ionizable lipids including other types of amines are included:
- the size of the prepared lipid nanoparticles is uniform (or has a low PDI value);
- the alkyl-epoxide may have a structure as shown in Formula 1 below.
- the alkyl-epoxide may have a carbon length of C6 to C14, C6 to C12, C6 to C10, C8 to C14, C8 to C12, C8 to C10, C10 to C14, C10 to C12, or C10, for example, For example, it may be 1,2-epoxydodecane of C10.
- the ionizable lipid may have the general formula of Formula 2 below.
- the structure of Formula 2 is an example of the structure of the ionizable lipid according to an embodiment, and the structure of the ionizable lipid may be different depending on the type of the 6-membered heterocyclic amine and/or the alkyl-epoxide.
- an ionizable lipid including an ionizable lipid having the structure of Formula 2 when included, it may have one or more of the following characteristics than in the case of lipid nanoparticles including other types of ionizable lipids:
- the size of the prepared lipid nanoparticles is uniform (or has a low PDI value);
- the lipid nanoparticles included in the pharmaceutical composition may have a pKa of 5 to 8, 5.5 to 7.5, 6 to 7, or 6.5 to 7.
- pKa is an acid dissociation constant, and points out what is generally used as an index
- the pKa value of the lipid nanoparticles is important in terms of in vivo stability of the lipid nanoparticles and drug release of the lipid nanoparticles.
- the lipid nanoparticles exhibiting a pKa value in the above range can be safely delivered to cancer tissues and/or cancer cells in vivo, reach cancer tissues and/or cancer cells, and exhibit a positive charge after endocytosis to endo It is possible to release the encapsulated drug (the first anticancer drug) through electrostatic interaction with the anionic protein of the endosome membrane.
- the phospholipid may serve to protect the core formed by the interaction of ionizable lipid and drug (first anticancer agent) in the lipid nanoparticles, and bind to the phospholipid bilayer of the target cell to form a cell membrane during intracellular delivery of the drug It can facilitate passage and endosomal escape.
- any phospholipid capable of promoting the fusion of lipid nanoparticles may be used without limitation, for example, dioleoylphosphatidylethanolamine (DOPE), distearoylphosphatidylcholine (DSPC) , palmitoyloleoylphosphatidylcholine (POPC), egg phosphatidylcholine (EPC), dioleoylphosphatidylcholine (dioleoylphosphatidylcholine, DOPC), dipalmitoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DOPC) ), dipalmitoylphosphatidylglycerol (DPPG), distearoylphosphatidylethanolamine (DSPE), phosphatidylethanolamine (PE), dipalmitoylphosphatidylethanolamine (dipalmitoylphosphatidylethanolamine), 1,2-diolep
- lipid nanoparticles including DOPE when including lipid nanoparticles including DOPE, it may be effective for mRNA delivery (excellent drug delivery efficiency for mRNA) as a drug, and in another example, when including lipid nanoparticles including DSPE As a drug, it may be effective for siRNA delivery (excellent drug delivery efficiency for siRNA).
- the cholesterol imparts morphological rigidity to the lipid filling in the lipid nanoparticles, and may serve to improve the stability of the nanoparticles by being dispersed in the core and surface of the nanoparticles.
- lipid-PEG (polyethyleneglycol) conjugate refers to a form in which a lipid and PEG are conjugated, It refers to a lipid in which a polyethylene glycol (PEG) polymer, which is a hydrophilic polymer, is bound to one end.
- PEG polyethylene glycol
- the lipid-PEG conjugate contributes to the stability of the nanoparticles in serum in the lipid nanoparticles, and serves to prevent aggregation between nanoparticles.
- the lipid-PEG conjugate protects the nucleic acid from degrading enzymes during in vivo delivery of the nucleic acid, thereby enhancing the stability of the nucleic acid in the body, and increasing the half-life of the drug encapsulated in the nanoparticles.
- the PEG may be conjugated directly to the lipid or may be linked to the lipid via a linker moiety.
- Any linker moiety suitable for linking PEG to a lipid can be used, including, for example, ester-free linker moieties and ester-containing linker moieties.
- the ester-free linker moiety is an amido (-C(O)NH-), amino (-NR-), carbonyl (-C(O)-), carbamate (-NHC(O)O-) ), urea (-NHC(O)NH-), disulfide (-SS-), ether (-O-), succinyl (-(O)CCH 2 CH 2 C(O)-), succinamidyl ( -NHC(O)CH 2 CH 2 C(O)NH-), ethers, disulfides, as well as combinations thereof (eg, linkers containing both carbamate linker moieties and amido linker moieties)
- the present invention is not limited thereto.
- ester-containing linker moieties include, for example, carbonate (-OC(O)O-), succinoyl, phosphate esters (-O-(O)POH-O-), sulfonate esters, and these including, but not limited to, combinations of
- the average molecular weight of the lipid-PEG conjugate is 100 to 10000 Daltons, 200 to 10000 Daltons, 500 to 10000 Daltons, 1000 to 10000 Daltons, 1500 to 10000 Daltons, 2000 to 10000 Daltons, 100 to 7500 Daltons, 200 to 7500 Daltons, 500 to 7500 Daltons, 1000 to 7500 Daltons, 1500 to 7500 Daltons, 2000 to 7500 Daltons, 100 to 5000 Daltons, 200 to 5000 Daltons, 500 to 5000 Daltons, 1000 to 5000 Daltons, 1500 to 5000 Daltons, 2000 to 5000 Daltons, 100 to 3000 Daltons, 200 to 3000 Daltons, 500 to 3000 Daltons, 1000 to 3000 Daltons, 1500 to 3000 Daltons, 2000 to 3000 Daltons, 100 to 2600 Daltons, 200 to 2600 Daltons, 500 to 2600 Daltons, 1000 to 2600 Daltons, 1500-2600 Daltons, 2000-2600 Daltons, 100-2500 Daltons, 200-2500 Daltons, 500-2500 Daltons, 1000-2500 Daltons, 1500-2500 Daltons,
- the lipid in the lipid-PEG conjugate may be used without limitation as long as it is a lipid capable of binding to polyethylene glycol, and phospholipids and/or cholesterol, which are other components of the lipid nanoparticles, may also be used.
- the lipid in the lipid-PEG conjugate is ceramide (ceramide) (ceramide), dimyristoylglycerol (DMG), succinoyl-diacylglycerol (s-DAG), distearoylphosphatidylcholine , DSPC), distearoylphosphatidylethanolamine (DSPE), or cholesterol.
- the lipid-PEG conjugate is PEG bound to dialkyloxypropyl (PEG-DAA), PEG bound to diacylglycerol (PEG-DAG), PEG bound to phospholipids such as phosphatidylethanolamine (PEG- PE), PEG conjugated to ceramide (PEG-CER, or ceramide-PEG conjugate), PEG conjugated to cholesterol or derivatives thereof, PEG-c-DOMG, PEG-DMG, PEG-DLPE, PEG-DMPE, PEG-DPPC , PEG-DSPE, and mixtures thereof, for example, C16-PEG2000 ceramide, DMG-PEG 2000, 14:0 PEG2000 PE.
- PEG-DAA dialkyloxypropyl
- PEG-DAG PEG bound to diacylglycerol
- PEG-PE PEG bound to phospholipids
- PEG-PE PEG conjugated to ceramide
- PEG-CER PEG conjugated to cholesterol or derivatives thereof
- the lipid nanoparticles including the ceramide-PEG conjugate when included, the lipid nanoparticles including other types of lipid-PEG conjugates may have one or more of the following characteristics than when the lipid nanoparticles are included:
- the size of the prepared lipid nanoparticles is uniform (or has a low PDI value);
- PEG in the lipid-PEG conjugate is a hydrophilic polymer and has the ability to inhibit the adsorption of plasma proteins, thereby increasing the circulation time of lipid nanoparticles in the body and preventing aggregation between nanoparticles.
- the lipid-PEG conjugate may exhibit a stealth function in vivo to prevent degradation of nanoparticles.
- the PEG may be a functional group bound to a side not bound to a lipid (functionalized PEG).
- the functional group that can be used is at least one selected from the group consisting of succinyl, carboxylic acid, maleimide, amine, biotin, cyanur, and folate.
- the lipid-PEG conjugate is 0.1 to 20 mol%, 0.25 to 20 mol%, 0.5 to 20 mol%, 1 to 20 mol%, 1.5 to 20 mol%, 2 to 20 mol%, 2.5 to 20 mol%, 3-20 mol%, 0.1-15 mol%, 0.25-15 mol%, 0.5-15 mol%, 1-15 mol%, 1.5-15 mol%, 2-15 mol%, 2.5-15 mol% , 3 to 15 mol%, 0.1 to 12.5 mol%, 0.25 to 12.5 mol%, 0.5 to 12.5 mol%, 1 to 12.5 mol%, 1.5 to 12.5 mol%, 2 to 12.5 mol%, 2.5 to 12.5 mol%, 3 to 12.5 mol%, 0.1 to 10 mol%, 0.25 to 10 mol%, 0.5 to 10 mol%, 1 to 10 mol%, 1.5 to 10 mol%, 2 to 10 mol%, 2.5 to 10 mol%, 3 to 10 mol%, 0.1 to 10 mol%,
- the drug delivery effect or cancer prevention and/or treatment effect of the lipid nanoparticles into cancer tissues and/or cancer cells may depend on the content of the lipid-PEG conjugate included in the lipid nanoparticles.
- 0.1-20 mol%, 0.25-20 mol%, 0.5-20 mol%, 1-20 mol%, 1.5-20 mol%, 2-20 mol%, 2.5-20 mol% of the lipid-PEG conjugate 3 to 20 mol%, 0.1 to 15 mol%, 0.25 to 15 mol%, 0.5 to 15 mol%, 1 to 15 mol%, 1.5 to 15 mol%, 2 to 15 mol%, 2.5 to 15 mol%, 3 to 15 mol%, 0.1 to 12.5 mol%, 0.25 to 12.5 mol%, 0.5 to 12.5 mol%, 1 to 12.5 mol%, 1.5 to 12.5 mol%, 2 to 12.5 mol%, 2.5 to 12.5 mol%, 3 to 12.5 mol%, 0.1-10 mol%, 0.25-10 mol%, 0.5-10 mol%, 1-10 mol%, 1.5-10 mol%, 2-10 mol%, 2.5-10 mol%, 3-10 mol% , 0.1 to 7.5 mol%, 0.25 to
- the size of the produced particles is uniform (or has a low PDI value);
- the cholesterol is 10 to 60 mol%, 20 to 60 mol%, 30 to 60 mol%, 34.5 to 60 mol%, 35 to 60 mol%, 39.5 to 60 mol%, 40 to 60 mol%, 43-60 mol%, 44-60 mol%, 10-55 mol%, 20-55 mol%, 30-55 mol%, 34.5-55 mol%, 35-55 mol%, 39.5-55 mol%, 40- 55 mol%, 43-55 mol%, 44-55 mol%, 10-52.5 mol%, 20-52.5 mol%, 30-52.5 mol%, 34.5-52.5 mol%, 35-52.5 mol%, 39.5-52.5 mol%%, 40-52.5 mol%, 43-52.5 mol%, 44-52.5 mol%, 10-51 mol%, 20-51 mol%, 30-51 mol%, 34.5-51 mol%, 35-51 mol%, 39.5 to 51 mol%, 40 to 51 mol%, 43 to 51 mol
- the sum of the lipid-PEG conjugate and the cholesterol is 40 to 60 mol%, 40 to 55 mol%, 40 to 53.5 mol%, 40 to 50 mol%, 40 to 47.5 mol%, 40 to 45 mol% %, 40 to 44,5 mol%, 42 to 60 mol%, 42 to 55 mol%, 42 to 53.5 mol%, 42 to 50 mol%, 42 to 47.5 mol%, 42 to 45 mol%, 42 to 44, 5 mol%, 44-60 mol%, 44-55 mol%, 44-53.5 mol%, 44-50 mol%, 44-47.5 mol%, 44-45 mol%, 44-44.5 mol%, 44.5-60 mol %, 44.5 to 55 mol%, 44.5 to 53.5 mol%, 44.5 to 50 mol%, 44.5 to 47.5 mol%, or 44.5 to 45 mol% may be included in the lipid nanoparticles.
- the ionizable lipid is 10 to 60 mol%, 10 to 55 mol%, 10 to 50 mol%, 10 to 45 mol%, 10 to 42.5 mol%, 10 to 40 mol%, 10 to 35 mol% %, 10-30 mol%, 10-26.5 mol%, 10-25 mol%, 10-20 mol%, 15-60 mol%, 15-55 mol%, 15-50 mol%, 15-45 mol%, 15 to 42.5 mol%, 15 to 40 mol%, 15 to 35 mol%, 15 to 30 mol%, 15 to 26.5 mol%, 15 to 25 mol%, 15 to 20 mol%, 20 to 60 mol%, 20 to 55 mol%, 20-50 mol%, 20-45 mol%, 20-42.5 mol%, 20-40 mol%, 20-35 mol%, 20-30 mol%, 20-26.5 mol%, 20-25 mol% %, 25-60 mol%, 25-55 mol%, 25-50 mol%,
- the phospholipid is 5 to 30 mol%, 5 to 25 mol%, 5 to 20 mol%, 5 to 15 mol%, 5 to 13 mol%, 5 to 10 mol%, 10 to 30 mol%, 10-25 mol%, 10-20 mol%, 10-15 mol%, 10-13 mol%, 15-30 mol%, 15-25 mol%, 15-20 mol%, 20-30 mol%, or 20 to 25 mol% may be included in the lipid nanoparticles.
- mol% (mol%, mole percent) is expressed as a percentage by dividing the number of moles of a specific component by the sum of moles of all components and then multiplying by 100.
- the lipid nanoparticles are ionizable lipid: phospholipid: cholesterol: lipid-PEG conjugate in a molar ratio of 20 to 50: 10 to 30: 10 to 60: 0.25 to 10, 20 to 50: 10 to 30: 20 to 60: 0.25 to A molar ratio of 10, 20 to 50: 10 to 30: 30 to 60: A molar ratio of 0.5 to 5, 25 to 45: 10 to 25: 40 to 50: A molar ratio of 0.5 to 3, 25 to 45: 10 to 20: 40 to 55: 0.5 to 3 molar ratio, 25 to 45: 10 to 20: 40 to 55: 1.0 to 1.5 molar ratio, 40 to 45: 10 to 15: 40 to 45: 0.5 to 3.0 molar ratio, 40 to 45: 10 to 15: 40 to 45: a molar ratio of 0.5 to 3, 40 to 45: 10 to 15: 40 to 45: a molar ratio of 1 to 1.5, 25 to 30: 17 to 22; 50 to 55: a molar ratio of 0.5 to 3.0,
- the moles of cholesterol are decreased as much as the number of moles of the lipid-PEG conjugate is increased, thereby maintaining the molar ratio of the components.
- the molar ratio means the mole ratio
- the lipid nanoparticles may include 20 to 50 parts by weight of an ionizable lipid, 10 to 30 parts by weight of a phospholipid, 30 to 60 parts by weight of cholesterol, and 0.1 to 5 parts by weight of a lipid-PEG conjugate.
- part by weight means a weight ratio in which each component is included.
- the lipid nanoparticles may comprise 20 to 50% by weight of an ionizable lipid, 10 to 30% by weight of a phospholipid, 40 to 60% by weight of a cholesterol, and 1.5 to 3% by weight of a lipid-PEG conjugate, based on the total weight of the nanoparticles. .
- the lipid nanoparticles include 25 to 50% by weight of ionizable lipids, 10 to 20% by weight of phospholipids, 35 to 55% by weight of cholesterol, and 0.5 to 5.0% by weight of lipid-PEG conjugates, based on the total weight of the nanoparticles. can do.
- a pharmaceutical composition comprising lipid nanoparticles comprising ionizable lipids, cholesterol, phospholipids, and/or lipid-PEG conjugates in the above ranges (molar ratios, midranges, and/or weight % ranges) outside of the above ranges ionizable lipids, (i) the stability of the lipid nanoparticles than when including lipid nanoparticles comprising cholesterol, phospholipids, and/or lipid-PEG conjugates; (ii) the encapsulation rate of the anticancer agent; (iii) efficiency of delivery of anticancer agents to cancer tissues and/or cancer cells; (iv) effect of long circulation in vivo; and/or (iv) cancer prevention and/or treatment effects may be excellent.
- the "targeting" and “localization” of the lipid nanoparticles to cancer tissues and/or cancer cells may be internalization in tissues or cells, and may also penetrate the nuclear membrane. It could mean internalizing it inside the nucleus.
- the pharmaceutical composition may be one in which a first anticancer agent (eg, an anionic drug and/or a physiologically active material such as a nucleic acid) is encapsulated inside the lipid nanoparticles, and the first anticancer agent is stable and highly efficient in the lipid It is encapsulated in nanoparticles and may exhibit excellent cancer prevention and/or treatment effects by the pharmaceutical composition according to an embodiment.
- a first anticancer agent eg, an anionic drug and/or a physiologically active material such as a nucleic acid
- the weight ratio of the ionizable lipid and the first anticancer agent (eg, anionic drug, nucleic acid, or a combination thereof) contained in the lipid nanoparticles is 1 to 20: 1, 1 to 15: 1, 1 to It may be 10:1, 5 to 20:1, 5 to 15:1, 5 to 10:1, 7.5 to 20:1, 7.5 to 15:1, or 7.5 to 10:1.
- the first anticancer agent eg, anionic drug, nucleic acid, or a combination thereof
- the composition according to an embodiment comprises (1) ionizable lipids in a weight ratio within the above range; and (2) a first anticancer agent (eg, anionic drug, nucleic acid, or a combination thereof), when (i) a first anticancer agent inside the lipid nanoparticle (eg, anionic drug, nucleic acid, or a combination thereof) ) of the encapsulation rate; (ii) efficiency of delivery of anticancer agents to cancer tissues and/or cancer cells; (iii) long circulation effect in vivo; and/or (iv) a cancer preventive and/or therapeutic effect in a weight ratio outside the above range: (1) an ionizable lipid; and (2) a composition comprising lipid nanoparticles comprising the first anticancer agent (which may be superior to).
- a first anticancer agent eg, anionic drug, nucleic acid, or a combination thereof
- the lipid nanoparticles encapsulated with the first anticancer agent have an average diameter of 20 nm to 200 nm, 20 to 180 nm, 20 nm to 170 nm, 20 nm to 150 nm, 20 nm to 120 nm, 20 nm to 100 nm, 20 nm to facilitate introduction into cancer tissues and/or cancer cells.
- Nanoparticles having a diameter within the above range can remain in the blood for a long time, so that the chance of reaching a target tumor tissue can be increased.
- Lipid nanoparticles having a diameter size in the above range may exhibit EPR (Enhanced Permeability and Retention; permeation increase and retention effect) effect.
- the EPR effect means that molecules having a specific size tend to accumulate in tumor tissues rather than normal tissues.
- Lipid nanoparticles having a diameter size within the above range are reduced in excretion to the kidney than lipid nanoparticles having a diameter size outside the above range, and immune cell activity is not induced, so that delivery to cancer cells and/or cancer tissues is effectively achieved.
- the composition comprising lipid nanoparticles having a diameter within the range is higher than the composition comprising lipid nanoparticles having a diameter exceeding the upper limit of the range (i) cancer tissue and/or cancer cell delivery efficiency ; (ii) increase the permeation and retention effect (EPR effect) into cancer tissues and/or cancer cells; and/or (iii) excellent in preventing and/or treating cancer.
- Lipid nanoparticles according to an embodiment are 5 to 8, 5.5 to 7.5, 6 to 7, or a first anticancer agent (for example, a nucleic acid and an anion) Sex drugs (eg, proteins))), etc., can easily form a complex with the drug through electrostatic interaction, so that the drug can be encapsulated with high efficiency, and the first anticancer agent (eg, nucleic acid) It can be usefully used as a composition for preventing and/or treating cancer, including.
- a first anticancer agent for example, a nucleic acid and an anion Sex drugs (eg, proteins)
- the first anticancer agent eg, nucleic acid
- encapsulation refers to encapsulating a delivery material to be efficiently encapsulated into the body, and the first anticancer agent (drug) encapsulation rate (encapsulation efficiency) is the total drug used for manufacturing. With respect to the content, it means the content of the first anticancer agent (drug) encapsulated in the lipid nanoparticles.
- the encapsulation rate of the first anticancer agent is 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 94% or more, 80% or more. 99% or less, 80% or more to 97% or less, 80% or more to 95% or less, 85% or more to 95% or less, 87% or more to 95% or less, 90% or more to 95% or less, 91% or more to 95% or less, 91% or more and 94% or less, 91% or more and 95% or less, 92% or more and 99% or less, 92% or more and 97% or less, or 92% or more and 95% or less.
- the encapsulation rate can be calculated by a commonly used method, for example, the first anticancer agent (drug) encapsulation rate is Triton-X treatment in the lipid nanoparticles according to an example, Triton-X is treated and Triton-X is not treated to measure the fluorescence intensity of a specific wavelength bandwidth (for example, exitation: 480 ⁇ 490nm, emission: 520 ⁇ 530nm), in Equation 2 below may have been calculated by
- Drug encapsulation rate (%) (Fluorescence intensity (fluorescence intensity) of lipid nanoparticles treated with Triton-X- Fluorescence intensity (fluorescence intensity) of lipid nanoparticles not treated with Triton-X)/(Triton-X treatment Fluorescence intensity (fluorescence intensity) of lipid nanoparticles) X 100
- the first anticancer agent may be an anionic drug, a nucleic acid, or a combination thereof that exhibits an effect of treating and/or preventing cancer.
- the nucleic acid is small interfering ribonucleic acid (siRNA), ribosomal ribonucleic acid (rRNA), ribonucleic acid (RNA), deoxyribonucleic acid (DNA), complementary deoxyribonucleic acid (cDNA), aptamer (aptamer), messenger ribonucleic acid (mRNA), It may be one or more selected from the group consisting of transport ribonucleic acid (tRNA), antisense oligonucleotide, shRNA, miRNA, ribozyme, PNA, DNAzyme, and sgRNA for gene editing, but is not limited thereto.
- tRNA transport ribonucleic acid
- antisense oligonucleotide shRNA
- miRNA miRNA
- ribozyme ribozyme
- PNA DNAzyme
- sgRNA messenger ribonucleic acid
- siRNA refers to double-stranded RNA (duplex RNA) capable of inducing RNA interference (RNAi) phenomenon through specific mRNA cleavage, or single-stranded single-stranded RNA having a double-stranded form inside single-stranded RNA. refers to RNA. It is composed of a sense RNA strand having a sequence homologous to the mRNA of a target gene and an antisense RNA strand having a sequence complementary thereto. Since siRNA can inhibit the expression of a target gene, it is provided as an efficient gene knock-down method or as a method of gene therapy. Bonding between double strands is achieved through hydrogen bonding between nucleotides, and not all nucleotides within the double strands need to be complementary and completely bonded.
- duplex RNA capable of inducing RNA interference (RNAi) phenomenon through specific mRNA cleavage, or single-stranded single-stranded RNA having a double-stranded form inside single-strand
- the length of the siRNA is about 15 to 60, specifically about 15 to 50, about 15 to 40, about 15 to 30, about 15 to 25, about 16 to 25, about 19 to 25, about 20 to 25, or about 20 to 23 nucleotides.
- the siRNA length means the number of nucleotides on one side of the double-stranded RNA, that is, the number of base pairs, and in the case of single-stranded RNA, it means the length of the double-stranded inside of the single-stranded RNA.
- siRNA may be composed of nucleotides introduced with various functional groups for the purpose of increasing blood stability or weakening an immune response.
- an "antisense oligonucleotide” may be modified at one or more bases, sugars or backbone positions to enhance efficacy (De Mesmaeker et al., Curr Opin Struct Biol., 5(3): 343-55, 1995).
- the oligonucleotide backbone can be modified with phosphorothioates, phosphotriesters, methyl phosphonates, short chain alkyls, cycloalkyls, short chain heteroatoms, heterocyclic intersaccharide linkages, and the like.
- Antisense oligonucleotides may also include one or more substituted sugar moieties.
- Antisense oligonucleotides may include modified bases.
- Modified bases include hypoxanthine, 6-methyladenine, 5-me pyrimidine (particularly 5-methylcytosine), 5-hydroxymethylcytosine (HMC), glycosyl HMC, gentobiosyl HMC, 2-aminoadenine, 2-thiouracil, 2-thiothymine, 5-bromouracil, 5-hydroxymethyluracil, 8-azaguanine, 7-deazaguanine, N6 (6-aminohexyl) adenine, 2,6-diaminopurine etc.
- single-stranded deoxyribonucleic acid refers to a single-stranded oligonucleotide that selectively binds to a specific target DNA and induces an antigene effect.
- aptamer refers to an oligonucleotide (generally, 20 to 80 nt DNA or RNA) that binds to a specific target.
- oligonucleotide aptamer eg, DNA or RNA aptamer.
- mRNA refers to a synthetic mRNA capable of expressing a gene (in vitro transcribed mRNA).
- RNA refers to nucleotides composed of 50 to 70 single strands, and in vivo forms a stem-loop structure.
- a long RNA of 19 to 29 nucleotides is complementary to both sides of a loop region of 5 to 10 nucleotides to form a double-stranded stem.
- miRNA refers to a single-stranded RNA molecule that regulates gene expression and consists of a full length of 21 to 23 nucleotides. miRNA is an oligonucleotide that is not expressed in cells and has a short stem-loop structure. miRNA has full or partial homology with one or two or more mRNA (messenger RNA), and suppresses target gene expression through complementary binding to the mRNA.
- miRNA messenger RNA
- ribozyme is a type of RNA and is an RNA having the same function as an enzyme that recognizes the base sequence of a specific RNA and cuts it by itself.
- a ribozyme is a complementary nucleotide sequence of a target messenger RNA strand and consists of a region that binds with specificity and a region that cuts the target RNA.
- DNAzyme is a single-stranded DNA molecule having enzymatic activity, and a DNAzyme (10-23 DNAzyme) consisting of 10 to 23 nucleotides cuts an RNA strand at a specific position under physiologically similar conditions. 10-23 DNAzyme does not base pair and cleaves between any exposed purines and pyrimidines. 10-23 DNA enzyme (DNAzyme) consists of 15 conserved nucleotide sequences (eg, 5'-GGCTAGCTACAACGA-3') of the enzyme's active site (catalytic domain) and the RNA substrate to the left and right of the active site of the above-mentioned enzyme. It consists of an RNA substrate binding domain consisting of 7 to 8 DNA sequences to be recognized.
- PNA protein nucleic acid
- PNA protein nucleic acid
- PNA Peptide nucleic acid
- PNA was first reported in 1999 as a DNA-like DNA in which nucleobases are linked by peptide bonds (Nielsen PE, Egholm M, Berg RH, Buchardt O, "Sequence-selective recognition of DNA by strand displacement with a thymine- substituted polyamide", Science 1991, Vol. 254: pp1497-1500]).
- PNA is not found in nature and is artificially synthesized by chemical methods.
- PNA causes a hybridization reaction with a natural nucleic acid of a complementary base sequence to form a double strand.
- PNA/DNA duplexes are more stable than DNA/DNA duplexes, and PNA/RNA duplexes are more stable than DNA/RNA duplexes for the same length.
- N-(2-aminoethyl)glycine is most commonly linked by amide bonds. is neutral with
- the four nucleotides present in PNA have almost the same spatial size and distance between the nucleotides as in the case of natural nucleic acids.
- PNA is not only chemically more stable than natural nucleic acids, but also biologically stable because it is not degraded by nucleases or proteases.
- sgRNA refers to a complex single RNA molecule of crispr RNA (crRNA) and tracer (tracrRNA) as an oligonucleotide (generally, an RNA molecule) that binds to a specific DNA target.
- crRNA crispr RNA
- tracrRNA tracer oligonucleotide
- gene editing protein refers to Cas9, spCas9, cjCas9, casX, CasY and Cpf1, and refers to a protein that recognizes a target DNA base sequence together with sgRNA to cause DNA cleavage.
- the composition for drug delivery according to an embodiment may include Cas9 mRNA at a high encapsulation rate.
- the previously known composition for delivery of Cas9 mRNA has a limitation in using it as a composition for delivery of Cas9 mRNA, including Cas9 mRNA at a low ratio.
- the lipid nanoparticles according to an embodiment may contain Cas9 mRNA with a high encapsulation rate, specifically, an encapsulation rate of 70% or more, and thus may be usefully utilized for gene editing therapy.
- the anionic drug may be anionic biopolymer-drug conjugates such as various peptides having an anion, protein drugs, protein-nucleic acid constructs or hyaluronic acid-peptide conjugates, hyaluronic acid-protein conjugates, and the like.
- the protein drug include gene editing proteins such as Cas 9 and cpf1, which are gene editing scissors, as well as apoptosis inducers (eg, cytocrome C, caspase 3/7/8/9, etc.) and various intracellular proteins. (eg, a transcription factor) and the like.
- the pharmaceutical composition for preventing or treating cancer may include lipid nanoparticles in which anionic drugs and/or nucleic acids are encapsulated.
- the cancer may be a cancer caused by infection with human papilloma virus (HPV).
- HPV human papilloma virus
- the cancer induced by HPV infection may include, but is not limited to, cervical cancer, vaginal cancer, vulvar cancer, anal cancer, penile cancer, tonsil cancer, pharyngeal cancer, laryngeal cancer, head and neck cancer, and adenocarcinoma of the lung. may be selected from the group.
- the cancer includes cervical cancer, endometrial cancer, vaginal cancer, vulva cancer, anal cancer, penis cancer, tonsil cancer, pharynx cancer, Larynx cancer, head and neck cancer, squamous cell head and neck cancer, lung adenocarcinoma, non-small cell lung cancer, squamous cell carcinoma of the lung, lung cancer, stomach cancer, sarcoma, lymphoma, Hodgkin's lymphoma, chronic or acute leukemia, thymus Cancer, epithelial cancer, salivary gland cancer, liver cancer, stomach cancer, thyroid cancer, parathyroid cancer, ovarian cancer, breast cancer, prostate cancer, esophageal cancer, pancreatic cancer, glioma, multiple myeloma, renal cell carcinoma, bladder cancer, choriocarcinoma, colon cancer, oral cancer, skin cancer, melanoma It may be selected from the group consisting of tumors, bone cancer, rectal cancer, small intestine cancer, endoc
- the pharmaceutical composition may be administered by various routes including parenteral administration to mammals including humans, and parenteral administration may be applied intravenously, subcutaneously, intraperitoneally or locally, and the dosage may vary depending on the patient's condition. and body weight, disease severity, drug form, administration route and time, but may be appropriately selected by those skilled in the art.
- the pharmaceutical composition When formulating the pharmaceutical composition according to an example, it is prepared using a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, and a surfactant usually used.
- a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, and a surfactant usually used.
- Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspension solutions, emulsions, lyophilized formulations, suppositories, and the like.
- Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate.
- injectable esters such as ethyl oleate.
- As the base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin, glycerol, gelatin, etc. may be used.
- the pharmaceutical composition according to an embodiment is administered in a pharmaceutically effective amount.
- pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is the type, severity, and drug activity of the patient. , can be determined according to factors including sensitivity to drug, administration time, administration route and excretion rate, duration of treatment, concurrent drugs, and other factors well known in the medical field.
- the pharmaceutical composition according to an embodiment may be administered as an individual therapeutic agent or may be administered in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered single or multiple. In consideration of all of the above factors, it is important to administer an amount that can obtain the maximum effect with a minimum amount without side effects, which can be easily determined by those skilled in the art.
- the effective amount of the compound according to the present invention may vary depending on the age, sex, and weight of the patient, and may be administered daily or every other day, or divided into 1 to 3 times a day. However, since it may increase or decrease depending on the route of administration, the severity of obesity, sex, weight, age, etc., the dosage is not intended to limit the scope of the present invention in any way.
- the pharmaceutical composition is 0.1 to 100 mg/kg, 0.1 to 50 mg/kg, 1 to 10 mg/kg based on the concentration of the drug (anionic drug, nucleic acid, or a combination thereof) included in the pharmaceutical composition. kg, or at a dose of 1 to 5 mg/kg.
- compositions for cancer treatment for use in combination with radiation therapy comprising the pharmaceutical composition; a pharmaceutical composition for enhancing radiation sensitivity;
- a pharmaceutical composition for cancer treatment in combination with radiation therapy may be provided.
- the pharmaceutical composition may further increase the effect of cancer treatment by improving the damage sensitivity of cancer cells to radiation during the treatment of cancer, and/or suppress the resistance of cancer cells to radiation to easily induce apoptosis of cancer cells by radiation It can be used as a composition or formulation that can be treated to do so, and a composition comprising the pharmaceutical composition can be used in combination with radiation therapy.
- the enhancement of radiation sensitivity means enhancing the sensitivity of cells to radiation in disease treatment using radiation.
- the radiation treatment efficiency can be increased, and in particular, when the treatment is performed concurrently during cancer treatment, the radiation sensitivity of cancer cells is enhanced, thereby making it possible to produce a killing effect and an inhibitory effect on the proliferation of cancer cells.
- a pharmaceutical composition for cancer treatment for use in combination with radiation therapy according to an embodiment is a first anticancer agent, HPV type 16 (HPV16) or HPV type 18 (HPV18) ) E6 and/or E7 proteins of the virus; phosphomevalonate kinase (PMVK) protein; or an inhibitor of expression or activity of a combination thereof.
- HPV type 16 HPV16
- HPV type 18 HPV18
- PMVK phosphomevalonate kinase
- the PMVK expression inhibitor, E6, and / or E7 expression inhibitor is an antisense nucleotide complementary to the mRNA of PMVK, E6, and / or E7 gene, small interfering RNA (siRNA), and short hairpin RNA ( short hairpin RNA; shRNA) may be selected from the group consisting of.
- said inhibitor of PMVK activity and/or said inhibitor of E6 and/or E7 activity of HPV16 (or HPV type 18) virus is a peptide that specifically binds to PMVK, E6, and/or E7 protein of HPV16 (or HPV type 18) virus.
- peptide mimetics, and aptamers may be selected from the group consisting of.
- the pharmaceutical composition may be administered in combination with radiation when treating cancer.
- the "irradiation" refers to a local treatment method that damages the DNA of malignant cells. Normal cells have a greater capacity to repair this damage than tumor cells. Irradiation refers to a treatment using such a difference, and includes a method of treatment using radiation in a conventional sense. Radiation irradiation can be divided into radical (red) radiation therapy, adjuvant radiation therapy, and palliative radiation therapy depending on the purpose of treatment.
- Curative (red) radiation therapy refers to radiation therapy for the purpose of cure when the tumor is relatively limited to a local area and there is no distant metastasis.
- Adjuvant radiation therapy refers to radiation therapy performed for the purpose of preventing local recurrence after surgical operation. By combining radiation therapy, it is possible not only to reduce recurrence, but also to reduce the scope of surgery to maintain function.
- Palliative radiation therapy is radiation therapy performed for the purpose of alleviating symptoms caused by cancer.
- Radiation is a treatment that uses high-energy radiation to kill cancer cells, but since it affects not only cancer cells but also normal tissues around them, side effects may occur due to treatment. Examples include skin changes, hair loss, nausea and vomiting, diarrhea, mucositis/esophagitis, dry mouth, and changes in reproductive function.
- a pharmaceutical composition for cancer treatment for use in combination with radiation therapy according to an embodiment; a pharmaceutical composition for enhancing radiation sensitivity; Alternatively, the pharmaceutical composition for cancer treatment in combination with radiation therapy may reduce these side effects by reducing the required amount of radiation.
- radiation sensitivity can be increased not only in cancer cells that are sensitive to radiation, but also in cancer cells that are resistant to radiation.
- Cancer for use in combination with radiation therapy comprising lipid nanoparticles comprising ionizable lipids, cholesterol, phospholipids, and/or lipid-PEG conjugates in ranges (molar ratio, midsection, and/or weight percent ranges) as described above.
- Pharmaceutical composition for treatment includes lipid nanoparticles comprising ionizable lipids, cholesterol, phospholipids, and/or lipid-PEG conjugates outside the above range
- 1,4-bis(3-aminopropyl)piperazine (1,4-bis(3-aminopropyl), and/or lipid nanoparticles comprising a ceramide-PEG conjugate In the case of other types of lipid-PEG conjugates, the sensitivity of cancer cells, tumor cells, and cancer tissues to radiation is increased, compared to the case of including lipid nanoparticles comprising a lipid-PEG conjugate, and thus cancer cell death and cancer treatment effects may be excellent.
- Another aspect is a pharmaceutical composition for combined administration of an anticancer agent, further comprising the pharmaceutical composition and a second anticancer agent; Or it may provide a pharmaceutical composition for enhancing anti-cancer treatment.
- the pharmaceutical composition is as described above.
- the second anticancer agent is gosipol, nitrogen mustard, imatinib, oxaliplatin, rituximab, erlotinib, neratinib, lapatinib, gefitinib, vandetanib, nirotinib, semasanib, bosutinib, axitinib , cediranib, restaurtinib, trastuzumab, gefitinib, bortezomib, sunitinib, carboplatin, bevacizumab, cisplatin, cetuximab, viscumalbum, asparaginase, tretinoin, hydroxycarba amide, dasatinib, estramustine, gemtuzumab ozogamicin, ibritumomab tuccetan, heptaplatin, methylaminolevulinic acid, amsacrine, alemtuzumab, pro
- the second anticancer agent may not be encapsulated inside the lipid nanoparticles included in the pharmaceutical composition.
- Another aspect is chemotherapy or radiation therapy for cancer, comprising co-administering the pharmaceutical composition when performing chemotherapy or radiation therapy for the treatment of cancer (eg, cancer caused by HPV infection). It is possible to provide a method for enhancing the sensitivity to cancer (eg, cancer caused by HPV infection). It is possible to provide a method for enhancing the sensitivity to cancer (eg, cancer caused by HPV infection).
- the step of administering the pharmaceutical composition several hours before, (eg, 4 hours) before chemotherapy may be performed first.
- the pharmaceutical composition may be administered 1 day after irradiation, several times over 2 days (eg 2 to 4 times).
- Another aspect provides a method for preventing or treating cancer comprising administering the pharmaceutical composition to a patient. Cancer is the same as described above.
- the method for preventing or treating cancer may further include the step of identifying (selecting) a patient in need of prevention and/or treatment of cancer before the administering step.
- the patient has received radiation and/or chemotherapy; patients receiving radiation and/or chemotherapy; and/or a patient scheduled to receive radiation therapy and/or chemotherapy.
- the subject subject to which the treatment method is applied means, but is not limited to, mammals including mice, livestock, etc. including humans that have or can develop cancer.
- a pharmaceutical composition comprising lipid nanoparticles comprising ionizable lipids, cholesterol, phospholipids, and/or lipid-PEG conjugates (or radiation treatment and / or a pharmaceutical composition for concurrent administration of an anticancer agent) to the subject, the subject can be efficiently treated.
- administration means introducing the pharmaceutical composition to a subject by any suitable method, and the route of administration is oral or parenteral (eg, intravenous, subcutaneous, intraperitoneal or topical application).
- the prevention or treatment method may include administering the pharmaceutical composition (or a pharmaceutical composition for combined administration of radiotherapy and/or anticancer agent) in a pharmaceutically effective amount.
- a suitable total daily amount may be determined by treatment within the scope of correct medical judgment, and may be administered once or divided into several doses.
- a specific therapeutically effective amount for a particular patient depends on the specific composition, age, weight, general health, sex and diet, administration time of the patient, including the type and extent of the response to be achieved, and whether other agents are used as the case may be.
- administration route and secretion rate of the composition, treatment period, various factors including drugs used together or concurrently with a specific composition, and similar factors well known in the pharmaceutical field can be applied differently.
- Another aspect includes administering the pharmaceutical composition to an animal (eg, an animal other than a human); And it relates to a treatment method for cancer comprising the step of irradiating radiation.
- an animal eg, an animal other than a human
- a treatment method for cancer comprising the step of irradiating radiation.
- the radiation treatment effect in the case of irradiating radiation after administration of the pharmaceutical composition, the radiation treatment effect, furthermore, the cancer treatment effect can be significantly enhanced according to the synergistic effect.
- the animal to be treated may be any mammal including humans, livestock, and pets, but is not limited thereto.
- any radiation method used for conventional radiation treatment of cancer or a radiation method for cancer to be developed later may be applied.
- Another aspect may provide a composition for killing cancer cells comprising the lipid nanoparticles and the first anticancer agent.
- Another aspect may provide a method for killing cancer cells comprising the step of encapsulating the first anticancer agent in the lipid nanoparticles.
- Cancer cells that can be killed by the composition according to an embodiment may refer to the aforementioned cancer cells.
- the pharmaceutical composition according to an embodiment has excellent biocompatibility, can deliver gene therapy with high efficiency, and thus has excellent cancer prevention or treatment effect, and excellent cancer prevention or treatment effect even when combined with other anticancer agents and/or radiation therapy do.
- FIG. 1a shows an exemplary structure of a lipid nanoparticle according to an example
- FIG. 1b shows an image observed by cryo-TEM of a nanoparticle according to an example.
- FIG. 3a (241-C10 LNP to 243-C10 LNP) and FIG. 3b (244-C10 LNP to 246-C10 LNP) show the results of measuring the fluorescence intensity of each lipid nanoparticle in a solution having a pH of 4.1 to 9.6. indicates
- FIGS. 4A and 4B are results showing the intracellular gene transfer efficiency of each nanoparticle.
- Figure 4a shows the luminescence intensity measured by lysing the cells after transforming the LNP containing the luciferase-encoding mRNA (luc mRNA) into HeLa cells
- Figure 4b shows the luminescence intensity measured by the encapsulation of siRNA according to an example. The results of measuring luciferase expression after LNP transformation into Hela-Luc cancer cells are shown.
- FIGS. 5A to 5C are results showing the gene transfer efficiency of nanoparticles in mice.
- Figure 5a shows the results of confirming the biodistribution in cancer tissues, liver and kidney by IVIS 48 hours after the fluorescence-attached siGFP was encapsulated with LNP and injected into a mouse model
- Figure 5b is a lipid containing siLuc. Nanoparticles are administered to Hela-Luc xenograft mouse model, and the increase or decrease in luciferase expression is measured with a bioluminescence device.
- Figure 5c is a bioluminescence chart showing the increase in luciferase expression according to the injection method after administration of lipid nanoparticles containing siLuc to a Hela-Luc xenograft mouse model.
- FIG. 6A shows the apoptosis effect of nanoparticles containing siRNA in a head and neck squamous cell carcinoma cell line and a cervical cancer cell line.
- 6B shows the increase or decrease in the expression of mRNA genes by nanoparticles containing siRNA in a head and neck squamous cell carcinoma cell line and a cervical cancer cell line.
- Figure 6c shows the increase or decrease in the expression of proteins by nanoparticles containing siRNA in a head and neck squamous cell carcinoma cell line and cervical cancer cell line.
- Figure 7a shows the apoptosis effect of nanoparticles containing siRNA in a pancreatic cancer cell line, a lung cancer cell line, a breast cancer cell line, and a cervical cancer cell line.
- Figure 7b shows the increase or decrease of mRNA gene expression by nanoparticles containing siRNA in a pancreatic cancer cell line, a lung cancer cell line, a breast cancer cell line, and a cervical cancer cell line.
- Figure 7c shows the increase or decrease of protein expression by nanoparticles containing siRNA in a pancreatic cancer cell line, a lung cancer cell line, a breast cancer cell line, and a cervical cancer cell line.
- FIG. 7D shows apoptosis by nanoparticles and radiation containing siRNA in a pancreatic cancer cell line, a lung cancer cell line, and a cervical cancer cell line.
- Figure 7e shows the increase or decrease of protein expression by nanoparticles and radiation containing siRNA in a pancreatic cancer cell line, a lung cancer cell line, and a cervical cancer cell line.
- FIG. 7f shows siRNA delivery and mRNA gene expression increase or decrease by nanoparticles containing siRNA against radiation in a pancreatic cancer cell line transplantation mouse model.
- FIG. 7G shows siRNA delivery and mRNA gene expression increase or decrease by nanoparticles containing siRNA against radiation in a lung cancer cell line transplantation mouse model.
- Example 1-1 Preparation of ionizable lipids
- An ionizable lipid was synthesized by reacting in a molar ratio of primary amine x 1).
- n primary amine x 2 + secondary amine x 1
- WELUX fine silica column Intertec, Korea
- Ionizable lipids prepared using 241 amines and C10 are named '241-C10', and ionizable lipids prepared using other types of amines are also named as 'Amine names used (241 to 246)-C10' did.
- Example 1-2 Identification of ionizable lipids produced
- Example 1-1 In order to confirm the ionizable lipid prepared in Example 1-1, 1 H NMR was performed. Specifically, 5 ⁇ g of the ionizable lipid (246-C10) synthesized in Example 1-1 was diluted in 0.5 ml of CDCl 3 (sigma, USA) to prepare a concentration of 100 mmole. Thereafter, 0.5 ml each was put into a 400 MHz NMR tube, the top was sealed, and then sealed with parafilm to obtain NMR spectra using Agilent 400 MHZ FT-NMR (Agilent, USA), and the results are shown in FIG. 2 . As shown in FIG. 2 , it was found that the signal representing each functional group of 246-C10 was saturated.
- MS analysis was performed. Specifically, MS analysis was performed by diluting ionizable lipids in ethanol to a concentration of 0.5 ppm or less.
- the instrument used for the analysis was 6230 LC/MS from Agilent Technologies (Palo Alto, USA), and Agilent Technologies' Zorbax SB-C18 (100 mm ⁇ 2.1 mm i.d., 3.5 ⁇ m) was used for the separation tube, and 0.1% of the mobile phase was used. Two solvents of distilled water (A) and acetonitrile (B) containing formic acid were gradient eluted.
- the solvent gradient of the mobile phase was maintained for 4 minutes until the ratio of the organic solvent acetonitrile (B) was initially increased from 30% to 80% until 2 minutes, and then the ratio of the organic solvent was lowered to 30% again and stabilized.
- the flow rate of the mobile phase was 300 ⁇ l/min, and the injection volume of the analyzer was 2 ⁇ l.
- Table 2 The results of MS analysis are shown in Table 2 below. As shown in Table 2, it was confirmed that the measured m/z ratio of the ionizable lipid and the calculated m/z ratio were almost identical.
- Ionizable lipids (241-C10 to 246-C10) prepared in Example 1-1, cholesterol (Cholesterol powder, BioReagent, suitable for cell culture, ⁇ 99%, sigma, Korea), phospholipids (DSPC) (Avanti, USA), and a lipid-PEG conjugate (C16-PEG2000 ceramide) (C16 PEG2000 Ceramide, Avanti, USA) were dissolved in ethanol in a molar ratio of 42.5:13:43:1.5.
- Ethanol and acetate buffer in which ionizable lipids, cholesterol, phospholipids, and lipid-PEG were dissolved were mixed at a volume ratio of 1:3 through a microfluidic mixing device (Benchtop Nanoassemblr; PNI, Canada) at a flow rate of 12 ml/min, Lipid nanoparticles (LNPs) were prepared.
- a microfluidic mixing device Benchtop Nanoassemblr; PNI, Canada
- Example 2-2 Preparation of nucleic acid-encapsulated lipid nanoparticles
- Ionizable lipids (241-C10 to 246-C10), cholesterol (Cholesterol powder, BioReagent, suitable for cell culture, ⁇ 99%, sigma, Korea), phospholipids (DSPC or DOPE) prepared in Example 1-1 ( 18:0 PC (DSPC), 18:1 ( ⁇ 9-Cis) PE (DOPE), Avanti, USA), and lipid-PEG conjugate (C16-PEG2000 ceramide) (C16 PEG2000 Ceramid, Avanti, USA) in ethanol dissolved.
- RNA therapeutic mRNA luciferase mRNA; SEQ ID NO: 1
- siRNA siLUC, siGFP, Anti-HPV16 E6/E7 siRNA, Anti-PMVK siRNA, etc.
- the aqueous phase was prepared by dilution in 0.75 mL of sodium.
- mRNA and siRNA were synthesized and used by Bioneer (Korea).
- lipid-PEG ionizable lipids, cholesterol, phospholipids, and a lipid-PEG conjugate
- a lipid-PEG conjugate hereinafter, lipid-PEG
- aqueous phase sodium acetate or sodium citrate
- an RNA therapeutic agent nucleic acid
- ionizable lipid phospholipid
- DOPE cholesterol: lipid-PEG (C16-PEG2000 ceramide) 26.5: 20: 52.5 to 51: 1.0 to 2.5 (molar ratio of It was dissolved in ethanol at a molar ratio of cholesterol and lipid-PEG content so that the total sum was 100), and the organic and aqueous phases were mixed so that the weight ratio of mRNA (luciferase
- ionizable lipid phospholipid (DSPC): cholesterol: lipid-PEG (C16-PEG2000 ceramide) to prepare siRNA-encapsulated lipid nanoparticles 42.5: 13: 34.5 to 44.25: 0.25 to 10.0 (total molar ratio It was dissolved in ethanol at a molar ratio of cholesterol and lipid-PEG content so that the sum was 100), and siRNA (siLUC, siGFP, Anti-HPV16 E6/E7 siRNA, Anti-PMVK siRNA, etc.): ionizable lipid was 1:7.5
- a lipid nanoparticle (LNP) was prepared by mixing an organic phase and an aqueous phase so as to have a weight ratio of .
- the sequences of the siRNAs used are shown in Table 3 below. Bases indicated by lowercase letters in Table 3 were transformed into 2'-O-Methyl.
- the prepared LNP was dialyzed against PBS for 16 hours using a 10,000 MWCO dialysis cassette to remove ethanol and adjust the pH of the lipid nanoparticles to the body pH.
- Lipid nanoparticles containing ionizable lipid '241-C10' were named '241-C10 LNP', and lipid nanoparticles prepared using ionizable lipids containing different types of amines (nucleic acid-encapsulated lipid nanoparticles particles) were named 'contained amine names (241 to 246)-C10 LNP'.
- Lipid nanoparticles encapsulated with siLuc were prepared as in Example 2-2 using a ceramide-PEG conjugate (C16-PEG2000 ceramide). Load 60ug of the prepared lipid nanoparticles (contains 1.5 mol% of ceramide-PEG conjugate) on 200 mesh carbon lacey film Cu-grid based on siRNA concentration, immerse in ethane liquefied with vitrobot (about -170 degrees or less) and plunge freeze After preparation, it was observed with Cryo-TEM (Tecnai F20, FEI), and the results are shown in FIG. 1B. As shown in FIG. 1b, spherical particles with a size of 100 nm or less were observed.
- Cryo-TEM Tecnai F20, FEI
- each lipid nanoparticle (LNP) formulated in Example 2-1 was calculated through an in vitro TNS assay.
- Anionic TNS interacts with positively charged ionizable lipids to become lipophilic, and as the pH value approaches the pKa value of each LNP, the lipophilicity of the TNS decreases and more water molecules quench TNS fluorescence ( quenching), lipid nanoparticles having a pKa of 6.0 to 7.0 have excellent in vivo drug delivery efficiency, and lipid nanoparticles showing an “s-shaped curve” in a graph showing fluorescence according to pH It means that the interaction is easy, and can easily escape the endosomes during acidification.
- the pH of a solution containing 20mM sodium phosphate, 25mM citrate, 20mM ammonium acetate, and 150mM NaCl is adjusted from pH 4.1 to pH 9.6 using 0.1N NaOH and/or 0.1N HCl at intervals of 0.5 to various pHs.
- a solution of the unit was prepared. 100 ⁇ l of each solution having each pH (pH with an interval of 0.5 from pH 4.1 to pH 9.6) was added to a black 96 well plate, and a TNS stock solution of 300 ⁇ M was used to obtain a final concentration of 6 ⁇ M. Each was added to a solution having a pH.
- 241-C10 LNP to 246-C10 LNP were added to the mixed solution to a final concentration of 20 uM.
- the fluorescence intensity was measured by excitation at 325 nm and emission at 435 nm through the Tecan instrument, and the fluorescence intensity for each lipid nanoparticle is shown in FIGS. 3A and 3B, and the pKa for each lipid nanoparticle reached half of the maximum fluorescence. It was calculated as the pH value and is shown in Table 4 below.
- FIG. 3b it was found that 244-C10 LNP to 246-C10 LNP exhibited a fluorescence titration s-shaped curve through nonlinear regression.
- the lipid nanoparticles according to one example exhibited excellent in vivo safety and drug release in the pKa range of 6.0 to 7.0.
- nucleic acid-encapsulated LNP prepared as in Example 2-2 the same pattern was shown depending on the type of ionizable lipid included (the type of amine included in the ionizable lipid).
- the size of the mRNA-encapsulated lipid nanoparticles (LNP; containing 1.5 mol% of lipid-PEG) prepared in Example 2-2 was measured.
- the RNA (luciferase mRNA; SEQ ID NO: 1) contained in each lipid nanoparticle prepared in Example 2-2 was diluted with PBS so that the concentration was 1 ⁇ g/ml, and Malvern Zetasizer Nano (Malvern Instruments, UK)
- the diameter and polydispersity index (PDI) of the LNPs were measured using dynamic light scattering (DLS) in the , and the results are shown in Table 5 below.
- Lipid nanoparticles Diameter (nm) PDI 241-C10 LNP 128 0.259 242-C10 LNP 77 0.210 243-C10 LNP 56 0.225 244-C10 LNP 66 0.149 245-C10 LNP 70 0.210 246-C10 LNP 68 0.143
- the encapsulation efficiency (drug encapsulation rate, %) of each LNP (containing 1.5 mol% of lipid-PEG) encapsulated with siRNA (siFVII siRNA) as a nucleic acid drug was measured by Ribogreen analysis (Quant-iTTM RiboGreen® RNA, Invitrogen). did The LNP containing the nucleic acid drug prepared in Example 2-2 was diluted with 50 ⁇ l of 1xTE buffer so that the final concentration of siRNA was 4 to 7 ⁇ g/ml in a 96-well plate.
- Triton-x LNP(-) For the group not treated with Triton-X (Triton-x LNP(-)), 50 ⁇ l of 1xTE buffer was added, and for the group treated with Triton-X (Triton-X LNP(+)), 2% Triton-X buffer 50 ⁇ l was added. After incubation at 37° C. for 10 minutes, LNPs were digested with Triton-X to release encapsulated nucleic acids. Then 100 ⁇ l of Ribogreen reagent was added to each well.
- the fluorescence intensity (FL) of Triton LNP(-) and Triton LNP(+) was measured with wavelength bandwidth (exitation: 485nm, emission: 528nm) in Infinite® 200 PRO NanoQuant (Tecan), and the drug encapsulation rate (encapsulation efficiency, %) ) was calculated as in Equation 3 below.
- the drug encapsulation rate (%) for each LNP is shown in Table 6 below as an average value of the results measured repeatedly twice.
- Drug encapsulation rate (%) (fluorescence of Triton LNP(+) - fluorescence of Triton LNP(-))/(fluorescence of Triton LNP(+)) X 100
- Lipid nanoparticles encapsulation rate (Encapsulation efficiency, %) 241-C10 LNP 84 242-C10 LNP 83 243-C10 LNP 91 244-C10 LNP 87 245-C10 LNP 91 246-C10 LNP 94
- Example 5-1 Nucleic acid delivery effect according to the type of ionizable lipid included in LNP
- HeLa cells Kerat Cell Line Bank
- DMEM media SH30022, Hyclone, USA
- LNP prepared in Example 2-2 in which mRNA (luc mRNA; SEQ ID NO: 1) encoding the luciferase gene was encapsulated (241-C10 LNP to 246-C10 LNP containing 1.5 mol% of lipid-PEG) ) was stirred with ApoE3 0.1 ⁇ g/ml and pipetting, incubated at room temperature for 10 minutes, and then treated with HeLa cells (100 ng/well based on mRNA contained in lipid nanoparticles).
- ApoE3 binds to the LNP surface and plays a role in allowing LNP to enter the cell through endocytosis through the LDL receptor expressed on the cell surface.
- FIG. 4A 244-C10 LNPs, 245-C10 LNPs, and 246-C10 LNPs with a pKa range of 6.0 to 7.0 showed strong luminescence intensity, and among them, 246-C10 LNP showed luminescence intensity. The highest, it was found that 246-C10 LNP had the highest intracellular drug delivery efficiency.
- Lipid nanoparticles were prepared in the same manner as in Example 2-2 by changing the content of lipid-PEG to 1.5 to 10.0 mol% by including C16 PEG-ceramide or PEG-DSPE in the lipid nanoparticles.
- the weight ratio of ionizable lipid: siRNA contained in lipid nanoparticles was 7.5: 1, and ionizable lipid (246-C10): phospholipid (DSPC): cholesterol: lipid-PEG (C16-PEG2000 ceramide or PEG contained in LNP)
- DSPC phospholipid
- cholesterol lipid-PEG (C16-PEG2000 ceramide or PEG contained in LNP)
- the molar ratio of -DSPE was 42.5: 13: 39.5 to 43: 1.5 to 5.0 (the cholesterol and lipid-PEG content were adjusted so that the sum of the molar ratios was 100).
- HeLa cells Kerat Cell Line Bank
- DMEM media SH30022, Hyclone, USA
- siLuc SEQ ID NOs: 2 and 3
- siLuc SEQ ID NOs: 2 and 3
- 100 ⁇ l/well of Bright-GloTM Luciferase Assay solution (promega, USA) was treated for 10
- the lysed cells were measured for luminescence intensity using an Infinite M200 luminescence measuring instrument (Tecan, USA), and the results are shown in FIG. 4B.
- the sequence of the used siLuc is shown in Table 3 above.
- the lipid nanoparticles according to one example had excellent nucleic acid delivery effect to Hela-Luc cells, which are cancer cells.
- Anti-HPV16 E6/E7 siRNA (SEQ ID NOs: 6 and 7; Table 3) encapsulated lipid with a content of lipid-PEG contained in the lipid nanoparticles of 1.5 to 5.0 mol% as in the method of Example 2-2 Nanoparticles were prepared.
- the weight ratio of ionizable lipid: siRNA contained in the lipid nanoparticles was 7.5: 1, and the ionizable lipid (246-C10): phospholipid (DSPC): cholesterol: lipid-PEG (C16-PEG2000 ceramide) contained in the LNP was The molar ratio was 42.5:13:39.5 to 43:1.5 to 5.0.
- the diameter and PDI of the lipid nanoparticles prepared above were measured in the same manner as in Example 4-1, and are shown in Table 7 below.
- Lipid-PEG (mol%) Average diameter (nm) PDI 5.0 67.4 0.312 1.5 122.9 0.214
- LNPs encapsulated with siHPV16_E6/E7 have a higher peak blood concentration (Cmax) after drug administration, a longer drug elimination half-life (T1/2), and a longer drug clearance (CL) compared to naked siRNA. ), which is maintained for a long time in the body and the degree of drug loss is low, increasing in vivo stability.
- Lipid nanoparticles (246-C10 LNPs) encapsulated with Cy5.5 labeled siGFP (SEQ ID NOs: 4 and 5; Table 3) were prepared with a content of lipid-PEG contained in the lipid nanoparticles of 5.0 mol%.
- the weight ratio of ionizable lipid: siRNA contained in the lipid nanoparticles was 7.5: 1, and the ionizable lipid (246-C10): phospholipid (DSPC): cholesterol: lipid-PEG (C16-PEG2000 ceramide) contained in LNP was The molar ratio was 42.5:13:39.5:5.0.
- the diameter and PDI of the lipid nanoparticles prepared above were measured in the same manner as in Example 4-1, and are shown in Table 9 below.
- Lipid-PEG (%) Average diameter (nm) PDI 5.0 30 0.142
- Example 5-5 Confirmation of in vivo siRNA delivery and gene regulation in Xenograft tumor mouse model
- Example 5-2 As confirmed in Example 5-2, the in vivo drug delivery efficiency and biodistribution of 246-C10 LNP, which exhibits excellent gene expression effect (gene transfer effect) in vitro, was to be confirmed in this Example.
- siLuc (SEQ ID NOs: 2 and 3; Table 3) was prepared as 246-C10 LNP (containing 1.5 mol% of lipid-PEG) according to the method of Example 5-4, and each nanoparticle was dialyzed in PBS for 16 hours. Ethanol was removed.
- siLuc lipid nanoparticles and negative control siRNA were injected into mice, and the bioluminescence intensity was shown in FIG. 5B using IVIS (PerkinElmer, USA) equipment 48 hours after injection.
- IVIS PerkinElmer, USA
- FIG. 5B it was confirmed that the group administered with the complementary siLuc lipid nanoparticles in vivo of HeLa-Luc xenograft mice had a decrease in luminescence intensity than the group administered with the negative control siRNA lipid nanoparticles.
- the delivery and preservation power of the lipid nanoparticles according to one example were excellent.
- siLuc (SEQ ID NOs: 2 and 3; Table 3) was prepared as 246-C10 LNP (containing 1.5 mol% of lipid-PEG) according to the method of Example 5-4, and each nanoparticles were dialyzed in PBS for 16 hours. Ethanol was removed. A Xenograft mouse model was manufactured in the same manner as in FIG. 5B, and the bioluminescence intensity according to the injection method was measured.
- Example 6-1 Preparation of lipid nanoparticles encapsulating siRNA targeting HPV16 E6/E7 gene
- Example 6-2 Measurement of cancer cell killing effect
- UM-SCC-47 (Meark Cat No. SCC071) cells, a head and neck squamous carcinoma (HNSCC) cell line, and Ca Ski (ATCC Cat No. CRL-1550) cell line was transfected with the LNP containing the Anti-HPV16 E6/E7 siRNA prepared in Example 6-1.
- DMEM medium Hyclone's Cat: SH30243.01
- Ca Ski a cervical cancer cell line
- RPMI Hyclone's Cat: SH30027.01
- the cancer cell killing effect by the lipid nanoparticles encapsulated with siRNA was excellent, and the killing effect was further increased when combined with an anticancer agent (CDDP).
- CDDP anticancer agent
- Example 6-3 mRNA expression measurement
- the mRNA expression of HPV 16 E6/E7 was measured, and the cancer prevention or treatment effect by the lipid nanoparticles according to the example was measured.
- p21 mRNA expression was measured.
- UM-SCC-47 (Meark Cat No. SCC071) cells, a head and neck squamous carcinoma (HNSCC) cell line, and Ca Ski (ATCC Cat No. CRL- 1550) was transfected with the LNP containing the Anti-HPV16 E6/E7 siRNA prepared in Example 6-1.
- the head and neck squamous cell line UM-SCC-47 and the cervical cancer cell line Ca Ski was cultured as in Example 6-2.
- p21 and p53 protein expression was measured in order to confirm the cancer prevention or treatment effect of the lipid nanoparticles according to an embodiment.
- UM-SCC-47 (Meark Cat No. SCC071) cells, a head and neck squamous carcinoma carcinoma (HNSCC) cell line, and Ca Ski (ATCC Cat No. CRL-1550) cell line was transfected with the LNP containing the Anti-HPV16 E6/E7 siRNA prepared in Example 6-1.
- UM-SCC-47, a cell line for head and neck squamous cell carcinoma, and Ca Ski a cell line for cervical cancer, were cultured as in Example 6-2.
- Example 7-1 Preparation of lipid nanoparticles encapsulating siRNA targeting PMVK
- Example 7-2 Measurement of cancer cell killing effect
- pancreatic cancer cell line Miapaca-2 (ATCC Cat.no CL-1420), the lung cancer cell line A549 (ATCC Cat.no CCL-185), and the breast cancer cell line MCF-7 (ATCC Cat.no HTB- 22), and a cervical cancer cell line, Hela (ATCC Cat.no CCL-2) cell line, was transfected with the LNP containing the Anti-PMVK siRNA prepared in Example 7-1.
- Pancreatic cancer cell line Miapaca-2 and cervical cancer cell line Hela were cultured in DMEM medium (Hyclone's Cat: SH30243.01) containing 10% fetal bovine serum and antibiotics at 37°C, 5% CO 2 and 100% humidity. .
- Lung cancer cell line A549 and breast cancer cell line MCF-7 were cultured in RPMI (Hyclone's Cat: SH30027.01) medium containing 10% fetal bovine serum and antibiotics at 37° C., 5% CO 2 and 100% humidity conditions.
- RPMI Hyclone's Cat: SH30027.01
- the cancer cell killing effect by siRNA was increased by the drug-encapsulated lipid nanoparticles according to an example.
- Example 7-3 mRNA expression measurement
- PMVK mRNA expression was measured in lung cancer, pancreatic cancer, breast cancer, and cervical cancer cells.
- pancreatic cancer cell line Miapaca-2 (ATCC Cat.no CL-1420), the lung cancer cell line A549 (ATCC Cat.no CCL-185), and the breast cancer cell line MCF-7 (ATCC Cat.no HTB- 22), and a cervical cancer cell line, Hela (ATCC Cat.no CCL-2) cell line, was transfected with the LNP containing the Anti-PMVK siRNA prepared in Example 7-1.
- Pancreatic cancer cell line Miapaca-2, cervical cancer cell line Hela, lung cancer cell line A549, and breast cancer cell line MCF-7 were cultured as in Example 7-2.
- the protein expression of PMVK was measured in lung cancer, pancreatic cancer, breast cancer, and cervical cancer cells.
- pancreatic cancer cell line Miapaca-2 (ATCC Cat.no CL-1420), the lung cancer cell line A549 (ATCC Cat.no CCL-185), and the breast cancer cell line MCF-7 (ATCC Cat.no HTB- 22), and a cervical cancer cell line, Hela (ATCC Cat.no CCL-2) cell line, was transfected with the LNP containing the Anti-PMVK siRNA prepared in Example 7-1.
- Pancreatic cancer cell line Miapaca-2, cervical cancer cell line Hela, lung cancer cell line A549, and breast cancer cell line MCF-7 were cultured as in Example 7-2.
- RIPA cell lysis buffer (RIPA cell lysis buffer: 150 mM NaCl, 10 mM Tris-HCl (pH 7.4), 5 mM EDTA, 0.1% SDS, 0.5% deoxycholate and 1% NP-40) was added and lysed, and the protein was Western blotting was performed with the same amount of protein through BCA assay that can quantify the amount.
- the primary antibody Anti-PMVK (Atlas antibody Cat no. HPA029900) was diluted 1:2000 and used.
- the secondary antibody the IgG-Mouse-HRP-conjugated antibody was diluted 1:5000 and the results are shown in FIG. 7c.
- Example 7-5 Measurement of survival rate by radiation sensitivity during PMVK knock-down in cancer cell lines
- the cell viability was measured when PMVK, known as a radiotherapy resistance-related factor, is knocked down in lung cancer, pancreatic cancer, and cervical cancer cells.
- pancreatic cancer cell line Miapaca-2 (ATCC Cat.no CL-1420), the lung cancer cell line A549 (ATCC Cat.no CCL-185), the cervical cancer cell line Hela (ATCC Cat.no CCL-2) and In Ca Ski (ATCC Cat.no CRL-1550) cell line, 246-C10 lipid nanoparticles ( Lipid-PEG containing 1 mol%) was prepared and transfected.
- Pancreatic cancer cell line Miapaca-2, cervical cancer cell line Hela, Ca Ski, and lung cancer cell line A549 were cultured as in Example 7-2.
- Miapaca-2, A549, HeLa, Ca Ski cells were seeded in a 96-well plate with 0.3 ⁇ 10 4 cells and cultured for 24 hours.
- the cultured cells were transfected with 246-C10 lipid nanoparticles (containing 1 mol% of lipid-PEG) containing the Anti-PMVK siRNA prepared in Example 7-5.
- 10 Gy of radiation was processed using a 6-MV photon beam linear accelerator. Cell viability was confirmed by CCK-8 assay on the second day after radiation treatment. The results are shown in Figure 7d.
- Example 7-6 Measurement of protein expression by radiation sensitivity during knock-down by PMVK nanoparticles in cancer cell lines
- protein expression was measured when PMVK, known as a radiation therapy resistance-related factor, was knocked down in lung cancer, pancreatic cancer, and cervical cancer cells.
- pancreatic cancer cell line Miapaca-2 (ATCC Cat.no CL-1420), lung cancer cell line A549 (ATCC Cat.no CCL-185), cervical cancer cell line Hela (ATCC Cat.no CCL-2) and The LNP containing the Anti-PMVK siRNA prepared in Example 7-5 was transfected into Ca Ski (ATCC Cat.no CRL-1550) cell line.
- Pancreatic cancer cell line Miapaca-2, cervical cancer cell line Hela, Ca Ski, and lung cancer cell line A549 were cultured as in Example 7-2.
- Miapaca-2, A549, HeLa, Ca Ski cells were seeded in a 6-well plate with 1.0 ⁇ 10 5 cells and cultured for 24 hours.
- the cultured cells were transfected with 246-C10 LNP (containing 1.0 mol% of lipid-PEG) containing the Anti-PMVK siRNA prepared in Example 7-5.
- 10 Gy of radiation was processed using a 6-MV photon beam linear accelerator. After the protein was extracted on the second day after radiation treatment, the expression of the protein was confirmed by performing Western blotting using the PMVK antibody. The results are shown in Figure 7e.
- Example 7-7 Confirmation of in vivo siRNA delivery and gene regulation by nanoparticles containing siRNA in a Xenograft tumor mouse model
- the tumor size change was measured when PMVK, known as a radiation therapy resistance-related factor, was knocked down in lung cancer and pancreatic cancer Xenograft mouse models.
- 246-C10 lipid nanoparticles containing 1 mol% of lipid-PEG
- siRNA SEQ ID NOs: 14 and 15; Table 3
- the tumor size reached 100mm 3 ⁇ 20
- PMVK-encapsulated 246-C10 lipid nanoparticles and Vehicle LNP were administered IV (Intravenous) in Miapaca-2 Xenograft nude mice at QD x 3 3mg/ kg and treated with 4 Gy of radiation using a 6-MV photon beam linear accelerator once a week after nanoparticle injection.
- the results are shown in 7f.
- 246-C10 lipid nanoparticles (containing 1 mol% of lipid-PEG) encapsulated with siRNA (SEQ ID NOs: 14 and 15; Table 3) targeting the PMVK gene were prepared.
- PMVK-encapsulated LNP and Vehicle LNP were injected IV (Intravenous) in A549 Xenograft nude mice in the first week and QD x 3 in the third week at 3 mg/kg, and also After nanoparticle injection, 2 Gy of radiation was treated using a 6-MV photon beam linear accelerator once a week.
- FIG. 7G. 7f and 7g it was confirmed that the decrease in PMVK gene expression in the mouse model administered with the 246-C10 lipid nanoparticles containing Anti-PMKV siRNA was further reduced when treated with radiation.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Nanotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Chemical formula |
Calculated
m/z ratio |
Observed
m/z ratio |
|
241-C10 | C32H66N2O2 | 510.87864 | 511.5201 |
242-C10 | C31H64N2O2 | 496.85206 | 497.5043 |
243-C10 | C31H65N3O2 | 511.8667 | 513.5186 |
244-C10 | C42H87N3O3 | 682.15848 | 682.6821 |
245-C10 | C43H89N3O3 | 696.18506 | 696.7045 |
246-C10 | C58H120N4O4 | 937.5978 | 937.9383 |
염기서열(5’->3’) | 서열번호 | ||
siLuc | sense | AAcGcuGGGcGuuAAucAAdTdT | 서열번호 2 |
antisense | UUGAUuAACGCCcAGCGUUdTdT | 서열번호 3 | |
Cy5.5 labeled siGFP | sense | ACAUGAAGCAGCACGACUUdTdT | 서열번호 4 |
antisense | AAGUCGUGCUGCUUCAUGUdTdT | 서열번호 5 | |
Anti-HPV16 E6/E7 siRNA | sense | GACCGGUCGAUGUAUGUCUUG | 서열번호 6 |
antisense | AGACAuACAuCGACCGGuCCA | 서열번호 7 | |
Anti-PMVK siRNA | sense | UGGACGAUGCUGAGUCAGAdTdT | 서열번호 14 |
antisense | UCUGACUCAGCAUCGUCCAdTdT | 서열번호 15 |
지질 나노입자 | pKa |
241-C10 LNP | 7.7 |
242-C10 LNP | 8.7 |
243-C10 LNP | 8.2 |
244-C10 LNP | 6.8 |
245-C10 LNP | 6.9 |
246-C10 LNP | 7 |
지질 나노입자 | 지름(nm) | PDI |
241-C10 LNP | 128 | 0.259 |
242-C10 LNP | 77 | 0.210 |
243-C10 LNP | 56 | 0.225 |
244-C10 LNP | 66 | 0.149 |
245-C10 LNP | 70 | 0.210 |
246-C10 LNP | 68 | 0.143 |
지질 나노입자 |
봉입률
(Encapsulation efficiency, %) |
241-C10 LNP | 84 |
242-C10 LNP | 83 |
243-C10 LNP | 91 |
244-C10 LNP | 87 |
245-C10 LNP | 91 |
246-C10 LNP | 94 |
지질-PEG (몰%) | 평균 지름 (nm) | PDI |
5.0 | 67.4 | 0.312 |
1.5 | 122.9 | 0.214 |
Naked |
246C10 Lipid
(지질-PEG 5%) |
246C10 Lipid
(지질-PEG 1.5%) |
|
T max (min) | 1.000 | 1.000 | 30.000 |
C max (ng/mL) | 146025.200 | 473280.700 | 289864.600 |
T 1/2 (min) | 3.384 | 87.321 | 588.182 |
CL (mL/min/kg) | 2.020 | 0.034 | 0.006 |
지질-PEG (%) | 평균 지름 (nm) | PDI |
5.0 | 30 | 0.142 |
프라이머 | 염기서열(5’->3’) | 서열번호 | |
HPV16_E6/E7 | Forward | CCACTGATCTCTACTGTTATGAGCAA | 서열번호 8 |
Reverse | CCAGCTGGACCATCTATTTCA | 서열번호 9 | |
P21 | Forward | CGAAGTCAGTTCCTTGTGGAG | 서열번호 10 |
Reverse | CATGGGTTCTGACGGACAT | 서열번호 11 | |
HPRT1 | Forward | TGACCTTGATTTATTTTGCATACC | 서열번호 12 |
Reverse | CGAGCAAGACGTTCAGTCCT | 서열번호 13 |
프라이머 | 염기서열(5’->3’) | 서열번호 | |
PMVK | Forward | ATATCCCCAGTGCCAGTCC | 서열번호 16 |
Reverse | AACAAGGGGCTGAGAACATC | 서열번호 17 | |
B-ACTIN | Forward | CCAACCGCGAGAAGATGA | 서열번호 18 |
Reverse | CCAGAGGCGTACAGGGATAG | 서열번호 19 |
Claims (16)
- (1) 1,4-비스(3-아미노프로필)피페라진(1,4-bis(3-aminopropyl)piperazine) 및 알킬-에폭시드가 결합된 이온화 가능한 지질 (ionizable lipid); 인지질; 콜레스테롤; 및 지질-PEG(polyethyleneglycol) 접합체를 포함하는 지질 나노입자 및(2) 제1 항암제를 포함하고,상기 제1 항암제는 음이온성 약물, 핵산, 또는 이의 조합인,암 예방 또는 치료용 약학 조성물.
- 제1항에 있어서, 상기 알킬-에폭시드는 1,2-에폭시도데칸(1,2-epoxydodecane)인, 약학 조성물.
- 제1항에 있어서, 상기 인지질은 DOPE, DSPC, POPC, EPC, DOPC, DPPC, DOPG, DPPG, DSPE, Phosphatidylethanolamine, dipalmitoylphosphatidylethanolamine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, POPE, POPC, DOPS, 및 1,2-dioleoyl-sn-glycero-3-[phospho-L-serine]으로 이루어진 군으로부터 선택되는 1종 이상인, 약학 조성물.
- 제1항에 있어서, 상기 지질-PEG 접합체 내 지질은 세라마이드(ceramide), 디미리스톨글리세롤(dimyristoylglycerol, DMG), 석시노일 디아글리세롤(succinoyl-diacylglycerol, s-DAG), 디스테아로일포스파티딜콜린(distearoylphosphatidylcholine, DSPC), 디스테아로일포스파티딜에탄올아민(distearoylphosphatidylethanolamine, DSPE), 및 콜레스테롤로 이루어진 군으로부터 선택되는 1종 이상인, 약학 조성물.
- 제1항에 있어서, 상기 지질-PEG 접합체를 0.25 내지 10 몰%로 포함하는, 약학 조성물.
- 제1항에 있어서, 상기 지질 나노입자는 이온화 가능한 지질 : 인지질 : 콜레스테롤 : 지질-PEG 접합체를 20 내지 50 : 10 내지 30 : 10 내지 60 : 0.25 내지 10 의 몰비로 포함하는, 약학 조성물.
- 제1항에 있어서, 상기 지질 나노입자는 pKa가 6.0 내지 7.0인, 약학 조성물.
- 제1항에 있어서, 상기 제1 항암제는 상기 지질 나노입자 내부에 봉입되어 있는, 약학 조성물.
- 제1항에 있어서, 상기 지질 나노입자는 평균 지름이 30nm 내지 150nm인, 약학 조성물
- 제1항에 있어서, 상기 음이온성 약물은 펩타이드, 단백질 약물, 단백질-핵산 구조체, 및 음이온성 생체고분자-약물 접합체로 이루어진 군에서 선택되는 1종 이상인, 약학 조성물.
- 제1항에 있어서, 상기 핵산은 소간섭리보핵산(siRNA), 리보좀 리보핵산(rRNA), 리보핵산(RNA), 디옥시리보핵산(DNA), 상보성 디옥시리보핵산(cDNA), 앱타머(aptamer), 전령 리보핵산(mRNA), 운반 리보핵산(tRNA), 안티센스 올리고뉴클레오티드, shRNA, miRNA, 리보자임(ribozyme), PNA, 및 DNAzyme로 이루어진 군에서 선택되는 1종 이상인, 약학 조성물.
- 제1항에 있어서, 상기 암은 HPV(human papilloma virus) 감염에 의해 유발된 암인, 약학 조성물.
- 제1항에 있어서, 상기 암은 자궁경부암, 자궁내막암, 질암(vagina cancer), 외음부암(vulvacancer), 항문암(anal cancer), 음경암(penis cancer), 편도암(tonsil cancer), 인두암(pharynx cancer), 후두암(larynx cancer), 두경부암, 편평 세포 두경부암, 폐의 선암(lung adenocarcinoma), 비소세포 폐암, 폐의 편평 세포 암종, 폐암, 위암, 육종, 림프종, 호지킨 림프종, 만성 또는 급성 백혈병, 흉선암, 상피암, 타액선암, 간암, 위암, 갑상선암, 부갑상선암, 난소암, 유방암, 전립선암, 식도암, 췌장암, 신경교종, 다발성 골수종, 신세포 암종, 방광암, 융모막암종, 결장암, 구강암, 피부암, 흑색종, 골암, 직장암, 소장암, 내분비선암, 부신암, 연조직 육종, 요도암, 척수 종양, 뇌간신경교종, 및 뇌하수체 선종으로 이루어지는 군에서 선택되는 것인, 약학 조성물.
- 제1항 내지 제13항 중 어느 한 항에 따른 약학 조성물을 포함하는, 방사선 치료에 병용하기 위한 암 치료용 약학 조성물.
- 제1항 내지 제13항 중 어느 한 항에 따른 약학 조성물 및 제2 항암제를 추가로 포함하는, 항암제 병용 투여용 약학 조성물.
- 제15항에 있어서, 상기 제2 항암제는 시스플라틴, 파크리탁셀, 도세탁셀, 젬시타빈, 독소루비신, 플루오로우라실, 및 카보플라틴으로 이루어지는 군에서 선택되는 1종 이상인, 항암제 병용 투여용 약학 조성물.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3205397A CA3205397A1 (en) | 2020-12-24 | 2021-12-23 | Composition for preventing or treating cancer, containing lipid nanoparticles |
EP21911591.2A EP4268851A1 (en) | 2020-12-24 | 2021-12-23 | Composition for preventing or treating cancer, containing lipid nanoparticles |
CN202180086566.9A CN117241836A (zh) | 2020-12-24 | 2021-12-23 | 包含脂质纳米颗粒的用于预防或治疗癌症的组合物 |
JP2023539065A JP2024500515A (ja) | 2020-12-24 | 2021-12-23 | 脂質ナノ粒子を含む癌の予防または治療用組成物 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0183898 | 2020-12-24 | ||
KR20200183898 | 2020-12-24 | ||
KR1020210153381A KR20220092363A (ko) | 2020-12-24 | 2021-11-09 | 지질 나노입자를 포함하는 암 예방 또는 치료용 조성물 |
KR10-2021-0153381 | 2021-11-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022139526A1 true WO2022139526A1 (ko) | 2022-06-30 |
Family
ID=82159965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/019773 WO2022139526A1 (ko) | 2020-12-24 | 2021-12-23 | 지질 나노입자를 포함하는 암 예방 또는 치료용 조성물 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP4268851A1 (ko) |
JP (1) | JP2024500515A (ko) |
CA (1) | CA3205397A1 (ko) |
WO (1) | WO2022139526A1 (ko) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080040412A (ko) * | 2006-11-03 | 2008-05-08 | 재단법인서울대학교산학협력재단 | 자궁경부암을 위한 치료용 조성물 |
WO2010053572A2 (en) * | 2008-11-07 | 2010-05-14 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
WO2013188763A1 (en) * | 2012-06-15 | 2013-12-19 | The Brigham And Women's Hospital, Inc. | Compositions for treating cancer and methods for making the same |
WO2019110067A1 (en) * | 2017-12-07 | 2019-06-13 | Aarhus Universitet | Hybrid nanoparticle |
-
2021
- 2021-12-23 WO PCT/KR2021/019773 patent/WO2022139526A1/ko active Application Filing
- 2021-12-23 CA CA3205397A patent/CA3205397A1/en active Pending
- 2021-12-23 EP EP21911591.2A patent/EP4268851A1/en active Pending
- 2021-12-23 JP JP2023539065A patent/JP2024500515A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20080040412A (ko) * | 2006-11-03 | 2008-05-08 | 재단법인서울대학교산학협력재단 | 자궁경부암을 위한 치료용 조성물 |
WO2010053572A2 (en) * | 2008-11-07 | 2010-05-14 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
WO2013188763A1 (en) * | 2012-06-15 | 2013-12-19 | The Brigham And Women's Hospital, Inc. | Compositions for treating cancer and methods for making the same |
WO2019110067A1 (en) * | 2017-12-07 | 2019-06-13 | Aarhus Universitet | Hybrid nanoparticle |
Non-Patent Citations (10)
Title |
---|
"Cas", Database accession no. 7209-38-3 |
DE MESMAEKER ET AL., CURR OPIN STRUCT BIOL., vol. 5, no. 3, 1995, pages 343 - 55 |
FILONANDPHILLIPS, BIOCHIM. BIOPHYS. ACTA, vol. 1329, 1997, pages 345 - 56 |
HIRKO ET AL., CURR. MED. CHEM., vol. 10, 2003, pages 1185 - 93 |
LOVE KEVIN T, MAHON KERRY P, LEVINS CHRISTOPHER G, WHITEHEAD KATHRYN A, QUERBES WILLIAM, DORKIN J ROBERT, QIN JUNE, CANTLEY WILLIA: "Lipid-like materials for low-dose, in vivo gene silencing", PROC NATL ACAD SCI, 2 February 2010 (2010-02-02), pages 1864 - 1869, XP055840232, Retrieved from the Internet <URL:https://www.pnas.org/content/pnas/107/5/1864.full.pdf> [retrieved on 20210913] * |
MERDAN ET AL., ADV. DRUG. DELIV. REV., vol. 54, 2002, pages 715 - 58 |
NIELSEN PEEGHOLM MBERG RHBUCHARDT O: "Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide", SCIENCE, vol. 254, 1991, pages 1497 - 1500, XP002912953, DOI: 10.1126/science.1962210 |
NOVINASHARP, NATURE, vol. 430, 2004, pages 161 - 164 |
REN ET AL., GENE THERAPY, vol. 7, 2000, pages 764 - 768 |
SPAGNOU ET AL., BIOCHEMISTRY, vol. 43, 2004, pages 13348 - 13356 |
Also Published As
Publication number | Publication date |
---|---|
CA3205397A1 (en) | 2022-06-30 |
EP4268851A1 (en) | 2023-11-01 |
JP2024500515A (ja) | 2024-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021145595A1 (ko) | 생체 내 약물 전달을 위한 지질 나노입자 및 이의 용도 | |
WO2019156365A1 (ko) | 엔도좀 탈출능을 갖는 펩티드 핵산 복합체 및 이의 용도 | |
WO2022139528A1 (ko) | 만노스를 포함하는 지질 나노입자 또는 이의 용도 | |
WO2018030789A1 (ko) | 세포투과성이 향상된 펩티드 핵산 복합체 및 이를 포함하는 약학적 조성물 | |
EP0789564B1 (en) | Polynucleotide compositions | |
WO2015002513A2 (ko) | 호흡기 질환 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 호흡기 질환 예방 또는 치료용 조성물 | |
WO2019156366A1 (ko) | 핵산 복합체를 함유하는 피부 투과성 전달체 및 이의 용도 | |
WO2017188731A1 (ko) | 경구 투여용 유전자 전달을 위한 나노입자 및 이를 포함하는 약학 조성물 | |
WO2013089411A1 (ko) | 유전자 나노 복합체 및 이를 이용한 유전자의 세포 내재화 방법 | |
WO2014169264A2 (en) | Nanoparticle mediated delivery of sirna | |
WO2019078611A1 (ko) | Cas9 단백질, SRD5A2 유전자의 발현을 억제하는 가이드 RNA 및 양이온성 폴리머의 복합체가 봉입된 나노 리포좀-마이크로버블 결합체 및 이를 함유하는 탈모 개선 또는 치료용 조성물 | |
WO2019225968A1 (ko) | 엠피레귤린 유전자 특이적 이중가닥 올리고뉴클레오티드 및 이를 포함하는 섬유증 관련 질환 및 호흡기 관련 질환 예방 및 치료용 조성물 | |
KR20220092363A (ko) | 지질 나노입자를 포함하는 암 예방 또는 치료용 조성물 | |
WO2023136688A1 (ko) | 생분해성 이황화 결합을 포함하는 이온화 가능한 지질 및 이를 포함하는 지질나노입자 | |
WO2022139526A1 (ko) | 지질 나노입자를 포함하는 암 예방 또는 치료용 조성물 | |
WO2022191377A1 (ko) | Sars-cov-2 예방 백신 조성물 | |
WO2023182756A1 (ko) | 신규한 이온화지질 및 이를 이용한 지질나노입자 조성물 | |
WO2023136689A1 (ko) | 생분해성 에스터 결합을 포함하는 이온화 가능한 지질 및 이를 포함하는 지질나노입자 | |
WO2015002512A1 (ko) | 뎅기 바이러스 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 뎅기 바이러스 증식 억제용 조성물 | |
WO2016068617A1 (ko) | 폴리올계 삼투압적 폴리디자일리톨 폴리머 유전자 전달체 및 이의 용도 | |
WO2020149644A1 (ko) | Dkk1 유전자를 표적으로 하는 이중나선 올리고뉴클레오티드, 이를 포함하는 구조체 및 이를 포함하는 탈모 예방 또는 발모용 조성물 | |
WO2020096234A1 (ko) | 피부 투과성 핵산 복합체를 유효성분으로 함유하는 아토피 피부염의 예방 또는 치료용 조성물 | |
WO2022191555A1 (ko) | Rna의 체내 전달용 조성물 및 이의 제조방법 | |
WO2022131744A1 (ko) | 펩티드 핵산 복합체를 유효성분으로 함유하는 췌장암 예방 또는 치료용 조성물 | |
WO2024144009A1 (ko) | 가지 친 구조의 이온화 지질을 포함한 지질 나노입자 제형 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21911591 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3205397 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180086566.9 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023539065 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021911591 Country of ref document: EP Effective date: 20230724 |